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II. STRUCTURE OF THE THESIS 
The thesis contains the three main chapters introduction, results and summarizing 
discussion. The introduction (chapter 1) is composed of two publications and chapters on 
brain cells. The results (chapter 2) include four publications and one manuscript. The 
publications are embedded as portable network graphics file made from portable 
document format files while the manuscript was not accepted at time of submission of the 
thesis and hence, is adapted to the style of the thesis. The results are discussed in 
summary (chapter 3).  
Figures and tables which are not part of a publication are numbered according the 
respective main chapter followed by the running number.  
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III. SUMMARY 
Iron oxide nanoparticles (IONPs) are used in various biomedical applications and are 
already applied in human therapy. Since IONPs can reach the brain, detailed knowledge 
on uptake and effects of IONPs on neural cells is required. In the present thesis, IONPs 
were synthesized and fluorescently labeled by attaching the green fluorescent dye 
BODIPY to the coating material dimercaptosuccinate. When 1.5% of the thiol groups of 
dimercaptosuccinate were functionalized, IONPs had identical physicochemical 
properties to the non-fluorescent version of the IONPs and were therefore considered as 
suitable fluorescent tool to study uptake and intracellular localization of 
dimercaptosuccinate-coated IONPs. 
Cellular uptake, localization and potential toxic effects of IONPs were investigated in cell 
culture models of the four major neural cell types (neurons, astrocytes, microglia, 
oligodendrocytes). In general, neural cell cultures efficiently accumulated IONPs which 
led to an increase of the specific cellular iron contents to maximal levels of up to 3000 
nmol iron per mg protein. The uptake of IONPs in cultured brain cells strongly 
depended on experimental conditions such as time of incubation, IONP concentration, 
temperature and on the absence or presence of serum. In the presence of serum, the 
accumulation of IONPs was decreased by 80-90% in all cell types investigated compared 
to serum-free conditions. Dependent on the cell type investigated, IONP uptake in 
presence of serum was strongly lowered by known inhibitors of endocytotic processes 
suggesting involvement of clathrin-mediated endocytosis and/or macropinocytosis. In 
contrast, for IONP uptake in absence of serum the pathways involved remain to be 
elucidated. 
A direct comparison of cultured astrocytes, neurons and microglia revealed that microglia 
were most efficient in IONP accumulation but also highly vulnerable to IONP exposure. 
Microglial cell death was prevented by neutralizing lysosomes or by chelating iron ions, 
suggesting that toxicity is mediated by rapid transfer of IONPs to lysosomes and fast 
IONP degradation in the acidic environment which resulted in microglial death by iron-
mediated oxidative stress. In contrast to microglia, primary astrocytes, neurons and 
oligodendroglial OLN-93 cells were not acutely damaged within hours upon IONP 
exposure. However, at least neurons which had accumulated substantial amounts of 
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IONPs during a short time exposure suffered from delayed toxicity after removal of 
exogenous IONPs.  
The data presented in this thesis reveal that brain cells deal well with low amounts of 
IONPs. However, higher iron contents after IONP exposure cause acute or delayed 
toxicity in some neural cell types. Among the different cell types, especially microglia 
were vulnerable to IONPs. Hence, concerning biomedical application of IONPs to the 
brain one should consider protecting microglia from IONP-derived stress to reduce or 
prevent potential adverse effects to the brain.  
 
Zusammenfassung  VII 
IV. ZUSAMMENFASSUNG 
Eisenoxidnanopartikel (IONPs) finden eine breite Anwendung in der Biomedizin und 
werden bereits für Therapien eingesetzt. Da IONPs das Gehirn erreichen können, ist 
eine detaillierte Kenntnis über ihre Aufnahme in und Wirkung auf Gehirnzellen wichtig. 
In der vorliegenden Arbeit wurden IONPs synthetisiert und fluoreszenzmarkiert. Dazu 
wurde der grün-fluoreszierende Farbstoff BODIPY an das Hüllmaterial 
Dimercaptobernsteinsäure angehängt. Die Menge an BODIPY in der Hülle hat einen 
großen Einfluss auf die Stabilität. Nach Markierung von 1.5% der Thiolgruppen der 
Dimercaptobernsteinsäure in der Hülle hatten diese IONPs identische physikochemische 
Eigenschaften wie die nicht-markierten IONPs. Daher sind BODIPY-markierte IONPs 
geeignet um die intrazelluläre Lokalisierung von Dimercaptobernsteinsäure-ummantelten 
IONPs zu untersuchen.  
Zelluläre Aufnahme, Lokalisierung und mögliche toxischen Effekte von IONPs wurden 
in Zellkulturmodellen der vier Hauptzelltypen des Gehirns (Neurone, Astrozyten, 
Microglia, Oligodendrozyten) untersucht. Im Allgemeinen akkumulierten neurale 
Zellkulturen IONPs effizient, was zu einem Anstieg ihres spezifischen zellulären 
Eisengehalts auf maximale Werte von bis zu 3000 nmol Eisen pro mg Protein führte. Die 
IONP-Aufnahme in Gehirnzellkulturen hing stark von den experimentellen Bedingungen 
wie Inkubationszeit, verwendete IONP-Konzentration, Temperatur und von der An- 
oder Abwesenheit von Serum ab. In der Anwesenheit von Serum nahm die 
Akkumulierung von IONPs im Vergleich zu serumfreien Bedingungen in allen 
untersuchten Zellkulturen um 80-90% ab. Die IONP-Aufnahme in Anwesenheit von 
Serum wurde durch bekannte Inhibitoren für endozytotische Wege stark verringert. Dies 
weist darauf hin, dass abhängig vom Zelltyp Clathrin-vermittelte Endozytose und/oder 
Macropinozytose an der IONP-Aufnahme in Gehirnzellen beteiligt sind. Im Gegensatz 
dazu müssen die für die IONP-Aufnahme verantwortlichen Wege in Abwesenheit von 
Serum noch aufgeklärt werden.  
Ein direkter Vergleich von kultivierten Astrozyten, Neuronen und Microglia zeigte, dass 
Microglia am effizientesten IONPs akkumulierten, aber auch besonders anfällig für 
IONP-vermittelte Toxizität waren. Ihr Zelltod konnte durch eine Neutralisierung der 
Lysosomen oder durch Chelatierung von Eisenionen verhindert werden. Dies lässt darauf 
schließen, dass die Toxizität durch schnellen Transport der IONPs zu Lysosomen und 
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schnellen IONP-Auflösung im sauren Milieu, was zu eisenvermittelten oxidativen Stress 
führt. Im Gegensatz zu Microglia wurden primäre Astrozyten, Neurone oder 
oligodendrogliale OLN-93-Zellen durch IONP-Exposition nicht akut innerhalb von 
wenigen Stunden geschädigt. Allerdings zeigten zumindest Neurone, welche substanzielle 
Mengen IONPs während einer kurzen Inkubationszeit akkumulierten, eine verzögerte 
Toxizität nach dem Entfernen von exogenen IONPs.  
Die Daten der vorliegenden Arbeit zeigen, dass Gehirnzellen gut mit geringen Mengen an 
IONPs umgehen können. Höhere Eisengehalte nach IONP-Behandlung können jedoch 
zu akuter oder verzögerter Toxizität führen. Unter den verschiedenen Gehirnzelltypen 
waren besonders Microglia anfällig für IONP-vermittelten Stress. Daher sollte für 
biomedizinische Anwendungen von IONPs ein Schutz der Microglia in Betracht gezogen 
werden um mögliche Schädigungen im Gehirn zu verhindern oder zu verringern. 
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Introduction  3 
1. Introduction 
1.1. Brain cells 
Brain cells can be divided into neurons and glial cells (Peters and Connor, 2014; Figure 
1). The glial cells are subdivided into astrocytes, oligodendrocytes and microglia. The 
ratio of glia to neurons in the human brain is a matter of debate. While some reviews 
state that glia, especially astrocytes, outnumber neurons by 10-fold without mentioning the 
source (Allen and Barres, 2009; Sofroniew and Vinters, 2010; Verkhratsky and Parpura, 
2010), other reports claim that the number of neuronal and non-neuronal cells are almost 
equal with around 86 billion neurons versus 84 billion non-neuronal cells (Azevedo et al., 
2009; Herculano-Houzel, 2014). However, the glia/neuron ratio is quite diverse in 
different parts of the brain such as cerebellum or cerebral cortex (Herculano-Houzel, 
2014).  
The following chapters will describe the physiology and function of neurons, astrocytes, 
microglia and oligodendrocytes and the commonly used cell culture models of these cell 
types. 
 
Figure 1.1 The four major cell types in the brain: neurons (yellow), 
oligodendrocytes (blue), astrocytes (green) covering a blood vessel (red), 
microglia (violet).   
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1.1.1. Neurons 
Neurons were firstly described by Jan Evangelista Purkinje in 1839 (Raine, 2006) and 
make up around 50% of the human brain (Azevedo et al., 2009; Herculano-Houzel, 
2014). They are composed of a perikaryon or soma, a varying number of branched 
dendrites and one axon which can be branched, thereby forming many synapses (Raine, 
2006). The neuronal somata are located in the grey matter whereas the white matter 
contains the axons (Raine, 2006). In general, neurons have the distinct function to 
transmit electrochemical signals. The action potential is built at the axon hillock by the all-
or-none-law by the influx of sodium ions through voltage gated sodium channels, resulting 
in a depolarization of the plasma membrane (Hille and Catterall, 2006). The signal is 
transferred along the axon to the axon terminal where neurotransmitters stored in vesicles 
are released by exocytosis into the synaptic cleft (Scalettar, 2006; Stevens and Williams, 
2000). Subsequently, neurotransmitters bind to receptors at the postsynaptic membrane 
of neighboring neurons and are cleaved (Chang et al., 1985; Silman and Sussman, 2005) 
or taken up to prevent permanent excitation (Balcar and Johnston, 1972; Palmer et al., 
2003; Kondratskaya et al., 2010). The binding of the neurotransmitter to the receptor 
leads to an either excitatory or inhibitory response of the postsynaptic neuron, thereby 
facilitating or hinder formation of action potentials, respectively (Holz and Fisher, 2006; 
Peters and Connor, 2014). The signal transduction is a highly energy consuming process 
but the axon can be very elongated (up to 1 m). Hence, there are complex trafficking 
mechanisms to transport mitochondria retrograde or anterograde along the axon (Sheng, 
2014).  
Neurons can differ regarding their morphology, location, function (motor, sensory) or 
effect (excitatory, inhibitory) (Holz and Fisher, 2006; Guerout et al., 2014; Pasca et al., 
2014). For example, cerebellar granule neurons possess a small soma (6-8 μm) (Monteiro 
et al., 1998; Raine, 2006) while the diameter of the soma of Purkinje cells is about 30 μm 
(Floeter and Greenough, 1979; Takacs and Hamori, 1994). Beside the size, the number 
and complexity of processes can differ extensively (Raine, 2006). Moreover, neurons can 
specialize to sensory neurons possessing specific receptors which are activated by a certain 
stimulus (Holz and Fisher, 2006) or to motor neurons which innervate muscles und 
stimulate muscle cells via the neuronal end plate (Grumbles et al., 2012; Tanaka et al., 
2014). The effect of neurotransmitters depends on the receptor in the postsynaptic 
membrane. Herein, one neurotransmitter can either excite or inhibit the postsynaptic 
neuron (Holz and Fisher, 2006).  
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1.1.2. Astrocytes 
In the beginning of glial research, astrocytes were thought to give only structural support. 
In the meanwhile, a variety of important astrocytic functions was discovered (Sofroniew 
and Vinters, 2010) and due to their morphological and physiological heterogeneity it is 
quite difficult to define what an astrocyte is (Kettenmann and Verkhratsky, 2011). 
Astrocytes are named by their often star-like morphology (Oberheim et al., 2012). The 
astrocytic end-feet cover the majority of the blood-brain barrier (BBB) which makes them 
the first neural cell type to get in contact with compounds passing the BBB (Virgintino et 
al., 1997; De Bock et al., 2014). They not only provide other neural cells with energy 
substrates, they also play a key role in the homeostasis of ions, pH and water (Kimelberg, 
2010; Sofroniew and Vinters, 2010) and they regulate the vasopressure in brain (De Bock 
et al., 2014; Howarth, 2014). Moreover, they interact with neurons and modulate their 
signal transmission. Considering the “tripartite synapse hypothesis”, the synapse is 
composed of the axonal terminal, the synaptic cleft, the postsynaptic membrane and 
additionally astrocytes in close proximity to the synapse. Due to expression of 
transporters astrocytes can actively take up neurotransmitters released from the synaptic 
cleft (Kettenmann and Verkhratsky, 2011; Roberts et al., 2014; Verkhratsky et al., 2014) 
to prevent neurons from excitotoxicity (Oberheim et al., 2012) or they can release 
gliotransmitters such as ATP, glutamate, serine or γ-amino butyric acid to modulate 
signaling (Verkhratsky and Parpura, 2010; Zhuang et al., 2011; Lee et al., 2013; De Bock 
et al., 2014). Astrocytes communicate with each other via intercellular calcium waves 
through gap junctions and hence, can modulate synaptic activity of distinct synapses (De 
Bock et al., 2014; Lallouette et al., 2014).  
Due to their location, astrocytes are the first neural cell type which comes into contact 
with xenobiotics crossing the BBB. Thus, they have also defense systems to metabolize 
and export xenobiotics (Dringen et al., 2015) and to protect neurons from stress (Wilson 
et al., 2000; Barreto et al., 2011; Genis et al., 2014). In case of cerebral injury, a glial scar 
is formed by reactive astrocytes which are characterized by strong expression of glial 
fibrillary acidic protein (GFAP) (Cregg et al., 2014; Liu et al., 2014) which is used as 
specific astrocytic marker although not all astrocytes express GFAP (Kettenmann and 
Verkhratsky, 2011). 
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1.1.3. Microglia 
The brain is described as immune privileged which means immune competent cells from 
the blood are excluded from the central nervous system (CNS) (Kettenmann et al., 2011). 
During early development mesodermal precursor cells enter the brain and differentiate 
into microglia which are macrophage-like cells and represent the immune competent cells 
of the CNS (Neumann and Wekerle, 2013; Nayak et al., 2014; Peters and Connor, 
2014). Due to their phagocytic properties, they incorporate pathogens (bacteria, viruses, 
fungi, parasites) invading the brain or they take up cell debris in case of apoptosis/necrosis 
of neural cells (Eyo and Dailey, 2013; Nayak et al., 2014). In the healthy CNS, microglia 
are “resting” and possess a ramified morphology while under pathological conditions they 
get activated and turn into an amoeboid shape which was firstly described by Pío del Río-
Hortega (Wilms et al., 1997; Biber et al., 2014). This activation might be induced by 
binding of certain compounds such as purines, released from injured neurons or glia, to 
specific receptors in the microglial membrane (Eyo and Dailey, 2013; Bernier et al., 
2013). In the activated state, microglia secrete anti- and pro-inflammatory cytokines such 
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) or nitric oxide (Kettenmann et 
al., 2011; Matsui et al., 2014; Pisanu et al., 2014).  
An important feature of microglia is their mobility, including migration of the whole cells 
and motility of the processes, thereby scanning their environment (Eyo and Dailey, 2013; 
Nayak et al., 2014). Microglia make 5% of glial cells in the grey matter (Pelvig et al., 2008) 
and they are in general regularly distributed within the brain possessing certain territories 
(Milligan et al., 1991; Neumann and Wekerle, 2013). However, if microglia become 
activated they guide surrounding microglia to the site of interference and start to 
proliferate to increase the number of microglia at the damaged location (Nayak et al., 
2014; Marlatt et al., 2014). Besides their neuroprotective nature, microglia play also a role 
during brain development, supporting the angiogenesis and controlling neuronal 
apoptosis and synaptic homeostasis (Eyo and Dailey, 2013; Nayak et al., 2014). 
Moreover, the activated state of microglia is discussed to be neurotoxic and associated 
with neurodegeneration and aging of the brain, though this is still a matter of debate 
(Biber et al., 2014).  
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1.1.4. Oligodendrocytes 
Oligodendrocytes are the most abundant glial cell type in the cerebral cortex (Pelvig et al., 
2008) and derive from oligodendrocyte precursor cells (Guerout et al., 2014; Pedraza et 
al., 2014). The differentiation of these precursor cells into mature oligodendrocytes is 
complex, involving loss of migration and proliferation and formation of processes (Bauer 
et al., 2009; Bradl and Lassmann, 2010). The unique function of mature 
oligodendrocytes is the myelination of neuronal axons by enwrapping the axons with 
several layers of membrane (Derobertis et al., 1958; Aggarwal et al., 2011). A single 
oligodendrocyte can ensheath 50 axons (Guerout et al., 2014) and completes its myelin 
sheaths within few days (Watkins et al., 2008). The production of the myelin which is 
composed of more than 70% lipids of the dry weight (Norton and Poduslo, 1973; 
Aggarwal et al., 2011) consumes a lot of energy and oxygen which results in generation of 
reactive oxygen species (ROS) (Bradl and Lassmann, 2010). As enzymes involved in 
myelination depend on iron as cofactor, oligodendrocytes are the neural cells with the 
highest iron content which makes oligodendrocytes vulnerable to oxidative stress caused 
by elevated ROS production via the Fenton reaction (Thorburne and Juurlink, 1996; 
Bradl and Lassmann, 2010).  
The myelin sheath is interrupted in regular intervals of 100 μm (Kettenmann and 
Verkhratsky, 2011), leaving the axon uncovered. These areas are called nodes of Ranvier. 
Since the myelin sheaths electrically isolate the axon, no action potential can form but at 
the nodes of Ranvier. This leads to saltatory signal conduction (Tasaki, 1939; Bradl and 
Lassmann, 2010) and to a dramatic increase in the speed which can otherwise only be 
achieved with very large unmyelinated axons with a diameter of 1 mm as in the giant 
squid (Kettenmann and Verkhratsky, 2011). Besides the isolation of the axons, myelin 
sheaths also influence neuronal structure and physiology such as axon diameter and 
transport rates along the axon (Bradl and Lassmann, 2010) and provide the axon with 
energy substrates such as lactate which is crucial for axonal health (Lee et al., 2012; 
Funfschilling et al., 2012; Morrison et al., 2013; Rinholm and Bergersen, 2013). 
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1.2. Culture models of brain cells 
Studying the metabolism of neural cells or effects of xenobiotics on brain is crucial to 
understand the function and pathology of the brain but is simultaneously complicated due 
to the complexity of the brain. Here, cell culture systems provide a convenient tool to 
investigate a variety of metabolic parameters in the cell type of interest also from certain 
brain regions under controlled culture conditions without the need of animal experiments 
(Hansson and Thorlin, 1999; Lange et al., 2012). Yet, in vitro studies lack of the three 
dimensional organization of the tissue, of cell cell interactions mainly between different 
cell types and the environment within the living organism (Hansson and Thorlin, 1999). 
Additionally, these systems are quite artificial such as culture medium which often has a 
completely different composition than the cerebrospinal fluid. This divergence from the 
in vivo situation has to be considered when interpreting the results. Nevertheless, 
analyzing the effect of compounds on brain cells in culture give a hint to what might 
happen in vivo (Sunol et al., 2008) and a lot of knowledge about brain cells was obtained 
by cultured neural cells (Lange et al., 2012; Tulpule et al., 2014). 
Most of brain cell cultures are obtained from rodents. There are diverse model systems 
for the different brain cells, most of them are primary (deriving directly from brain tissue) 
or secondary cultures (reseeded cells obtained from primary cultures). However, some 
research is also performed on cell lines which have some advantages such as no need of 
animals, easy culture techniques and nearly unlimited supply of cells due to cell division. 
On the other hand, cell lines are immortalized, having often cancerous origin which might 
imply an altered metabolism and different response to stimuli. Due to the different 
culturing techniques (tissue derived cells, cell lines, days in vitro, medium composition, 
coating of the plates etc.) it is important to use a cell culture system which is appropriate 
for the question or purpose (Lange et al., 2012). 
 
1.2.1. Neurons 
Primary neuron cultures are mainly obtained from distinct regions of the brain (e.g. 
hippocampus, cerebellum or cortex) rather than from the whole brain and might be 
either prepared from embryonal or from 7 d old rodents which depends on the brain 
region due to varying differentiation states (Sunol et al., 2008). Cultures of cortical and 
cerebellar granule neurons have been shown to not differ from each other with respect to 
respiration (Jameson et al., 1984) or chloride uptake (Sunol et al., 2008). In the present 
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thesis, cultures of cerebellar granule neurons (Figure 2a) were used. They express 
neuronal markers such as microtubule-associated protein 2 (Tulpule et al., 2014). Like 
the majority of neurons in vivo, cultured primary neurons do not divide after seeding but 
elongate their processes. As the yield of preparation of primary neuron cultures is 
relatively low (Sunol et al., 2008), many research groups use the cell line PC12 or to a 
lesser extent SH-SY5Y instead. They have rat phaeochromocytoma (Westerink and 
Ewing, 2008) and human neuroblastoma (Xie et al., 2010) as origin, respectively and are 
often used as a model for differentiating neurons but also to study metabolism and 
toxicity in neurons (Xie et al., 2010; Westerink and Ewing, 2008). 
 
 
Figure 2.1 Cell cultures of brain cells used in the present thesis: primary 
cerebellar granule neurons (a), OLN-93 cells (b), astroglia-rich primary 
culture (c; from chapter 2.1) and primary microglial cells (d). Pictures were 
captured using an Eclipse TE-2000U (a, b, c) or TS-100 (d) microscope from 
Nikon (Düsseldorf, Germany). The scale bars represent 100 μm. 
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1.2.2. Astrocytes 
Astrocytes are frequently used as primary or secondary culture (Lange et al., 2012) while 
C6 glioma cells are used a model for astroglioma cells (Barth and Kaur, 2009). Astroglia-
rich primary cultures (Figure 2b) are prepared from neonatal rodents (Hamprecht and 
Löffler, 1985) and are contaminated by other glial cells (chapter 2.1; Saura, 2007; Yoo 
and Wrathall, 2007). The heterogeneity of astrocytes within the living brain is challenging 
for culturing astrocytes and interpreting the experimental outcome (Lange et al., 2012). 
Already astroglia-rich primary cultures prepared from rats and mice respond differently 
under the same culture conditions (Ahlemeyer et al., 2013). Cultured astrocytes possess 
the same properties as astrocytes in brain such as glycogen formation (Dringen et al., 
1993), glutamate transport (Hertz et al., 1978) or storage of metal ions (Jones et al., 2012). 
While astrocytes in vivo express the astrocytic marker GFAP only in activated state (Cregg 
et al., 2014), cultured astrocytes are mainly GFAP-positive (Du et al., 2010). However, 
this depends on culturing conditions (chapter 2.1; Goetschy et al., 1986; Codeluppi et al., 
2011). To explore astrocyte behavior in diseases, different in vitro models are used such 
as scratch injury for trauma or oxygen glucose deprivation for ischemia (Yu et al., 1993; 
Wu and Schwartz, 1998; Giffard and Swanson, 2005; Lange et al., 2012).  
 
1.2.3. Microglia 
There are two major preparation techniques described to obtain microglial cultures. 
Mixed glial cultures contain besides astrocytes a certain amount of other glial cell such as 
oligodendrocytes, ependymal cells and microglia and these contaminating cells are either 
sitting on top of the astrocyte layer or underneath it (Saura et al., 2003; Yoo and Wrathall, 
2007). Hence, microglia can be isolated by shaking the culture for a certain time to detach 
the top layer microglia and subsequently, the microglia-containing medium is removed 
and used for seeding into new culture plates (Tamashiro et al., 2012; Deierborg, 2013). In 
the other method, the astrocytic layer is detached by trypsination and removed while the 
bottom layer microglia remain in the plate (Saura et al., 2003; Figure 2d). As their in vivo 
counterparts, cultured microglia are mobile (Jeon et al., 2012), express proteins for 
immune response such as CD11b (Szabo and Gulya, 2013) and release nitric oxide if they 
become activated (Saura et al., 2003). However, isolated microglia display in general 
amoeboid morphology as seen for activated microglia in vivo while microglia in mixed 
glial cultures are more ramified (Saura et al., 2003). Besides the described primary and 
Introduction  11 
secondary microglial cultures, cell lines such as BV2 or N9 which are derived from 
murine microglia and immortalized by viruses are used as microglial model systems 
(Stansley et al., 2012; Rodhe, 2013). These cell lines have the advantage that they 
overcome the low yield problem of the primary cultures while possessing the same 
microglial characteristics. Nevertheless, unlimited cell division might alter differentiation 
and properties (Rodhe, 2013). 
 
1.2.4. Oligodendrocytes 
Cultured oligodendrocytes are obtained similarly to microglia by shaking off top layer 
cells from astroglia-rich primary cultures (McCarthy and de Vellis, 1980; Barateiro and 
Fernandes, 2014). While microglia are more easily detaching than oligodendrocytes, 
there are often two shaking steps used to lower microglial contamination in the 
oligodendrocyte culture (Barateiro and Fernandes, 2014). As observed for 
oligodendroglial cells in vivo, also in culture these cells can be divided into 
oligodendrocyte progenitor cells, pre-oligodendrocytes, immature and mature 
oligodendrocytes, as characterized by morphology and expression of specific proteins 
(Jarjour et al., 2012; Barateiro and Fernandes, 2014). Oligodendrocytic differentiation can 
be provoked by e.g. thyroid hormone (Barateiro et al., 2013) or by the presence of axons 
in co-cultures (Barateiro and Fernandes, 2014). Compared to oligodendrocytes in vivo, 
cultured oligodendrocytes produce 500-times less area of myelin membrane (Jarjour et 
al., 2012). Oligodendrocyte culturing methods are limited by a very low cell yield and the 
fact that mature oligodendrocytes do not divide in vitro (Buntinx et al., 2003). Also here, 
cell lines are helpful. Herein, human clonal cell lines such as HOG, MO3.13 and KG-1C 
(Buntinx et al., 2003) as well as the rat cell line OLN-93 (Richter-Landsberg and 
Heinrich, 1996) are available. Advantageously, OLN-93 cells (Figure 2b) are not derived 
from a tumor as HOG and KG-1C but they are spontaneously transformed cells from 
primary glial cultures (Richter-Landsberg and Heinrich, 1996). OLN-93 cells possess 
markers for differentiated oligodendroglial cells such as galactocerebroside, myelin-
associated glycoprotein or myelin-basic protein though they resemble morphologically 
more oligodendrocyte progenitors and are able to proliferate (Richter-Landsberg and 
Heinrich, 1996). 
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1.2.5. Co-cultures and slice models 
Besides the conventional cell culture techniques described above there is emphasis to 
mimic the in vivo situation more realistically. To allow and investigate interactions 
between different neural cell types, co-cultures can be prepared (Jones et al., 2012; 
Welser and Milner, 2012; Jarjour et al., 2012). This type of cell culture was very useful to 
examine different aspects of interactions between cell types. For example, the release of 
glutathione and extracellular degradation by astrocytes supplies neurons with the 
precursors to synthesize glutathione intracellularly (Dringen et al., 1999). While 
cerebellar granule neurons in vitro express glutamine synthetase, an enzyme in vivo solely 
expressed in astrocytes (Norenberg and Martinez-Hernandez, 1979; Albrecht et al., 
2007), when deprived in glutamine, co-culturing with astrocytes reduced or abolished 
glutamine synthetase expression in neurons (Fernandes et al., 2010). Moreover, the 
formation of myelin by oligodendrocytes is enhanced by presence of astrocytes (Watkins 
et al., 2008).  
Additionally, ex vivo cultures of brain slices of around 200-500 μm thickness preserve the 
three dimensional organization of the brain and have been successfully used to identify 
the myelinating cell type in the CNS (Jarjour et al., 2012). To overcome the two 
dimensional culture model, there are approaches to culture brain cells three 
dimensionally on scaffolds (Kang et al., 2014; Lau et al., 2014; Weightman et al., 2014) or 
as neurospheres which are free floating aggregates of neural stem cells (Brito et al., 2012; 
Ghate et al., 2014). However, there will always be the drawback that human brain cell 
cultures are rare and the conclusions based on results from rodent cell cultures to human 
brain are hard to draw. 
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Abstract  
Iron oxide nanoparticles (IONPs) are used for various biomedical and neurobiological 
applications. Thus, detailed knowledge on the accumulation and toxic potential of IONPs 
for the different types of brain cells is highly warranted. Literature data suggest that 
microglial cells are more vulnerable towards IONPs exposure than other types of brain 
cells. To investigate the mechanisms involved in IONP-induced microglial toxicity we 
applied fluorescent dimercaptosuccinate-coated IONPs to primary cultures of microglial 
cells. Exposure to IONPs for 6 h caused a strong concentration-dependent increase in the 
microglial iron content which was accompanied by a substantial generation of reactive 
oxygen species (ROS) and by cell toxicity. In contrast, hardly any ROS staining and no 
loss in cell viability were observed for cultured primary astrocytes and neurons although 
these cultures accumulated similar specific amounts of IONPs than microglia. Co-
localization studies with lysotracker revealed that in microglial cells, but not in astrocytes 
and neurons, most IONP fluorescence was localized in lysosomes. ROS formation and 
toxicity in IONP-treated microglial cultures were prevented by neutralizing lysosomal pH 
by application of NH4Cl or Bafilomycin A1 and by application of the iron chelator 2,2’-
bipyridyl. These data demonstrate that rapid iron liberation from IONPs at acidic pH 
and iron-catalyzed ROS generation are involved in the IONP-induced toxicity of 
microglia and suggest that the relative resistance of astrocytes and neurons against acute 
IONP toxicity is a consequence of a slow mobilization of iron from IONPs in the 
lysosomal degradation pathway.  
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Introduction 
Iron oxide nanoparticles (IONPs) have gained substantial attention for biomedical 
applications and are already used as contrast agent in magnetic resonance imaging (MRI), 
for cancer treatment by hyperthermia or for targeted drug delivery (Li et al., 2013; 
Mahmoudi et al., 2011; Maier-Hauff et al., 2011). Nanoparticles can enter the brain via 
the intact or damaged blood-brain barrier, via the olfactory nerve or by direct injection 
into brain in the case of hyperthermia treatment (Petters et al., 2014b). By such 
applications all types of brain cells are likely to encounter IONPs in vivo.  
In addition to neurons which are responsible for signal transduction, transmit information 
along their axon and release neurotransmitters to other neurons (Peters and Connor, 
2014; Scalettar, 2006), the brain contains various types of glial cells in substantial numbers 
(Peters and Connor, 2014). Microglial cells are the immune competent cells of the brain 
and clear the brain from cell debris and intruders (Nayak et al., 2014; Eyo and Dailey, 
2013). In case of incident, microglial cells become activated, transform from their resting 
ramified into their amoeboid form and migrate to the site of interference (Kettenmann et 
al., 2011; Nayak et al., 2014). Astrocytes cover with their processes most of the brain 
capillaries which form the blood-brain barrier (De Bock et al., 2014), supply other brain 
cell types with nutrients (Bouzier-Sore and Pellerin, 2013; Stobart and Anderson, 2013), 
are responsible for the homeostasis of ions, water and metals (Verkhratsky et al., 2014; 
Dringen et al., 2013; Hohnholt and Dringen, 2013) and have important detoxifying 
functions in brain (Fernandez-Fernandez et al., 2012; Dringen et al., 2015).  
Several studies have investigated the uptake and biocompatibility of IONPs in culture 
models for the different types of brain cell, including primary cultures of astrocytes, 
neurons and microglial cells (for overview see: (Petters et al., 2014b)). However, data on a 
quantitative comparison of the uptake and cytotoxicity of IONPs in different types of 
brain cells are scarce. In brain cell culture systems, microglial cells have been reported to 
take up fluorescent nanospheres and IONPs more efficiently than astrocytes and neurons 
(Jenkins et al., 2013; Pinkernelle et al., 2012; Fernandes and Chari, 2014). In addition, in 
co-cultures IONP uptake into astrocytes and oligodendrocyte precursor cells was lowered 
in the presence of microglial cells (Pickard and Chari, 2010). In vivo, mainly macrophage-
like cells were found IONP-positive after injection of IONPs into human glioma (van 
Landeghem et al., 2009), supporting the hypothesis that microglial cells have also in vivo a 
high potential to accumulate IONPs. Macropinocytosis and clathrin-mediated endocytosis 
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have been identified as molecular mechanisms involved in the IONP uptake by microglial 
cells which direct the accumulated IONPs into the lysosomal degradation pathway 
(Luther et al., 2013). 
The strong accumulation of IONPs by microglia has been connected with a high 
vulnerability of these cells towards IONPs (Jenkins et al., 2013; Luther et al., 2013) while 
astrocytes (Geppert et al., 2012; Geppert et al., 2011; Jenkins et al., 2013) and neurons 
(Sun et al., 2013; Petters and Dringen, 2015) appear to be relative resistant against acute 
IONP toxicity. However, the mechanisms involved in the toxicity of IONPs for microglial 
cells and the reason for the apparent resistance of astrocytes and neurons against IONPs 
are currently unknown. To address such questions, we have exposed primary cultures of 
microglia, neurons and astrocytes under identical experimental conditions to fluorescent 
IONPs and directly compared the potential of the different neural cells for IONP 
accumulation as well as the potential of IONPs to compromise cell viability. Here, we 
report that cultured microglial cells accumulated low concentrations of fluorescent IONP 
more efficiently than astrocytes and neurons while high concentrations of IONPs caused 
severe ROS production and toxicity in microglial cells but not in astrocytes and neurons. 
IONP-induced damage of microglial cells was prevented by neutralization of the acidic 
lysosomal pH or by chelation of iron ions, suggesting that in microglial cells the rapid 
lysosomal mobilization of iron from internalized IONPs causes accelerated ROS 
formation and oxidative cell damage.  
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Material and methods 
Materials 
Dulbecco’s modified Eagle’s medium (DMEM) and minimal essential media (MEM) 
were from Gibco (Karlsruhe, Germany). Fetal calf serum (FCS) and 
penicillin/streptomycin solution were purchased from Biochrom (Berlin, Germany). 
Bovine serum albumin and NADH were from Applichem (Darmstadt, Germany) and 
Bafilomycin A1 was purchased from Invivogen (Toulouse, France). BODIPY FL C1-IA 
(BP) [N-(4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
yl)methyl)iodoacetamide] and lysotracker red DND-99 were from Life Technologies 
(Darmstadt, Germany). Other chemicals of the highest purity available were obtained 
from Merck (Darmstadt, Germany), Fluka (Buchs, Switzerland) or Sigma-Aldrich 
(Steinheim, Germany). 96-well microtiter plates and 6-well cell culture plates were 
purchased from Sarstedt (Nümbrecht, Germany) and Nunc (Wiesbaden, Germany), 
respectively.  
Synthesis and characterization of fluorescent IONPs 
Fluorescent dimercaptosuccinate (DMSA)-coated IONPs were synthesized and 
characterized as previously reported (Petters et al., 2014a). Briefly, maghemite IONPs 
were generated by an alkaline co-precipitation method (Geppert et al., 2009) and the 
IONPs were coated with BP-functionalized DMSA (Petters et al., 2014a). Single 
fluorescent IONPs were spherical and had a size of 4-20 nm as seen by transmission 
electron microscopy (Petters et al., 2014a). The fluorescent BP-DMSA-IONPs emit light 
at 510 nm after excitation at 490 nm (Petters et al., 2014a). 
The hydrodynamic diameter and the ζ-potential of IONPs in suspension were 
determined by dynamic and electrophoretic light scattering in a Beckman Coulter 
(Krefeld, Germany) DelsaTM Nano Particle analyzer at 25°C at scattering angle of 165° and 
15°, respectively. Concentrations of IONPs refer to the total concentration of iron in 
dispersion and not to the concentration of nanoparticles.  
Cell culture 
Microglial cultures were generated by tryptic removal of the astrocyte layer of astrocyte-
rich primary cultures in 6-well plates one day prior to experiments as described previously 
(Luther et al., 2013). The remaining attached microglia were washed once with culture 
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medium (90% DMEM, 10% fetal calf serum, 25 mM glucose, 1 mM pyruvate, 20 
units/mL penicillin G and 20 μg/mL streptomycin sulfate) and incubated in 2 mL glia-
conditioned medium (GCM) before incubations with IONPs were started. 
Immunocytochemical characterization of the microglial cultures revealed that more than 
98% of the cells in these cultures are positive for the microglial marker protein CD11b 
(Luther et al., 2013).  
Astrocyte-rich primary cultures were prepared from newborn Wistar rats as described 
recently in detail (Tulpule et al., 2014). Cells were seeded at a density of 375,000 
cells/well in 6-well plates and used at day five in culture for experiments. Astrocyte-rich 
cultures are strongly enriched in cells positive for the astrocyte marker protein glial 
fibrillary acidic protein, contain some microglial and oligodendroglial cells but no neurons 
(Petters and Dringen, 2014; Tulpule et al., 2014). 
Cerebellar granule neuron cultures were prepared from brains of 7 d-old Wistar rats as 
described recently in detail (Tulpule et al., 2014). The cells were seeded in neuron 
culture medium (90% MEM, 10% heat-inactivated FCS, 25 mM KCl, 30 mM glucose and 
2 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin) in a density of 
1,875,000 cells/well in 6-well plates. Neurons were used for experiments after seven days 
in culture. Immunocytochemical characterization of the neuron cultures revealed that 
99% of the cells expressed the neuronal marker protein microtubule-associated protein-2 
(Tulpule et al., 2014). 
Experimental incubations 
GCM is required to avoid toxicity of microglial cells in cultures (Saura et al., 2003). In 
order to establish comparable incubation conditions for primary microglial cells, neurons 
and astrocytes, all primary cultures were incubated in GCM. GCM was prepared as 
previously described (Luther et al., 2013) by incubating astrocyte-rich primary cultures in 
175 cm2 flasks for 1 d with 50 mL culture medium. The medium was harvested, filtered 
through a 0.2 μm sterile filter and stored at 4°C for not more than three weeks (Luther et 
al., 2013). In case of experiments on cerebellar granule neurons, the GCM had to be 
supplemented with 25 mM KCl to prevent neuronal apoptosis (Contestabile, 2002).  
To investigate acute consequences of IONPs on cultured primary neural cells, the 
cultures were incubated at 37°C in a humidified atmosphere with 10% CO2 in 1 mL GCM 
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without or with IONPs and/or other compounds as indicated in the legends of the figures 
and tables.  
After incubation, cells were washed once with 1 mL phosphate-buffered saline (PBS, 10 
mM potassium phosphate buffer, pH 7.4, containing 150 mM NaCl) and lysed in 1 mL 
1% (w/v) Triton X-100 in PBS to measure cellular lactate dehydrogenase (LDH) activity 
or in 700 μL 50 mM NaOH to determine cellular protein and iron contents.  
For cellular localization of fluorescent IONPs, cultures were incubated with 0.1 mM 
IONPs for 6 h followed by 90 min incubation with 100 nM lysotracker DND-99 as 
previously described (Luther et al., 2013). Cells were fixed with 3.5% (w/v) 
paraformaldehyde in PBS and washed twice prior to analysis of cellular fluorescence by 
microscopy. 
Determination of cell viability and ROS production 
The cell viability was investigated by determining the cellular LDH activity and the 
cellular MTT reduction capacity as well as by propidium iodide (PI) staining. The cellular 
LDH activity was determined as previously described (Tulpule et al., 2014; Dringen et al., 
1998). Aliquots of the Triton X-100 lysates were mixed with pyruvate and NADH and the 
decline in absorbance at 340 nm was measured using a Sunrise-Basic microtiter plate 
reader (Tecan, Grödig, Austria). As the presence of millimolar concentrations of IONPs 
in the incubation medium strongly disturbed the photometric LDH measurement (data 
not shown), cellular LDH activity and not LDH release from damaged cells was used to 
investigate loss of membrane integrity. Incubation of cells with up to 3 mM IONPs did 
not interfere with the measurement of the LDH activity in cell lysates while higher 
concentrations did (data not shown).  
The MTT reduction capacity was determined after a given incubation as described 
previously (Scheiber et al., 2010). Briefly, the cells were incubated with 1 mL 1 mg/mL 
MTT in GCM for 90 min, the formazan crystals dissolved in 1 mL dimethyl sulfoxide 
and the absorbance at 540 nm was determined. Under the conditions used, the presence 
of IONPs in cells did not affect the analysis of MTT reduction capacity (data not shown).  
For PI staining, the cells were incubated with 1 mL GCM containing 5 μM PI and 10 μM 
H33342 (Tulpule et al., 2014) for 15 min, washed once with PBS and monitored 
immediately by fluorescence microscopy. 
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Presence of cellular ROS was investigated by rhodamine staining. The fluorescent 
rhodamine 123 is generated in cells by the ROS-dependent oxidation of 
dihydrorhodamine 123 (Geppert et al., 2012). The cultures were washed with 1 mL 
incubation buffer (20 mM HEPES, 1.8 mM CaCl2, 1 mM MgCl2, 5.4 mM KCl, 145 mM 
NaCl, pH 7.4) and stained for 15 min with 1 mL 5 μg/mL dihydrorhodamine 123 and 10 
μM H33342 in incubation buffer. After the incubation cells were washed once with PBS 
and monitored immediately for fluorescence.  
 Determination of protein and iron content 
The protein content of the cultures was determined by the Lowry method (Lowry et al., 
1951) with bovine serum albumin as a standard. The iron content of IONP-treated 
cultures was measured by a modified ferrozine-based iron assay (Geppert et al., 2009). 
Briefly, 100 μL cell lysate was mixed with 100 μL 10 mM HCl and 100 μL of a solution 
containing 2.25% (w/v) KMnO4 and 0.7 M HCl. After incubation at 60°C for 16 h, 30 μL 
of a mixture of 1 M ascorbate, 2.5 M ammonium acetate, 6.5 mM ferrozine and 6.5 mM 
neocuproine in water was added and the absorbance at 540 nm was measured after 1 h. 
The iron content determined for a sample was normalized on the protein content of the 
respective sample.  
Fluorescence microscopy 
Stained cells were monitored for fluorescence using an Eclipse TE-2000U fluorescence 
microscope with a DS-QilMc camera (Nikon, Düsseldorf, Germany). The following filter 
sets were used for monitoring the BP-signal of fluorescent IONPs (excitation at 465-495 
nm, emission at 505-515 nm, dichromatic mirror at 505 nm), for the H33342 staining 
(excitation at 330-380 nm, emission at 420 nm, dichromatic mirror at 400 nm) and for 
visualizing the staining by PI, rhodamine and lysotracker DND-99 (excitation at 510-560 
nm, emission at 575 nm, dichromatic mirror at 590 nm).  
Presentation of data 
Quantitative data shown in figures and tables are means ± SD of values that were obtained 
in experiments that had been performed on n independently prepared cultures. 
Microscopic images are from representative experiments that were reproduced twice on 
independently prepared cultures with similar results. Signal intensities were increased 
using Adobe Photoshop 7.0 for better contrast. Significance of differences between 
groups of data was analyzed by ANOVA followed by the Bonferroni post-hoc test. 
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Analysis of significance of differences between two groups of data was done by the 
unpaired t-test. p>0.05 was considered as not significant.  
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1. Characterization of iron oxide nanoparticles 
Dispersions of BP-DMSA-coated IONPs in GCM which contained 10% FCS were 
colloidally stable. Compared to water dispersions, the IONPs dispersed in GCM had an 
increased hydrodynamic diameter, a broader size distribution as demonstrated by the 
increased polydispersity index, and a reduced negative surface charge as demonstrated by 
the less negative ζ-potential (table 1). This was expected as serum proteins are considered 
to form a protein corona around DMSA-coated IONPs which is accompanied by an 
increase in diameter and a lowering of the negative ζ-potential (Geppert et al., 2013; 
Petters et al., 2014a). The average hydrodynamic diameter of dispersions of 3 mM 
IONPs in GCM was around 160 nm and significantly increased compared to GCM 
dispersion of 1 mM IONPs (90 nm) which is consistent with the concentration-dependent 
alteration in particle size reported for citrate-coated IONPs in serum-containing culture 
medium (Safi et al., 2011). In contrast, polydispersity index and ζ-potential did not differ 
for IONPs dispersions in GCM containing 1 mM or 3 mM iron (table 1). Hydrodynamic 
diameter, polydispersity, and ζ-potential of IONPs were not affected if GCM was 
supplemented with additional 25 mM KCl for incubation of neurons (data not shown). 
2. Uptake and toxicity of iron oxide nanoparticles by microglial cells 
Previously was shown that exposure of cultured microglial cells to IONPs for up to 6 h 
caused a time-dependent increase in cellular iron content and compromised cell viability 
(Luther et al., 2013). In order to investigate the mechanisms involved in this toxicity, we 
applied fluorescent IONPs in concentrations between 0.1 mM and 3 mM to cultured 
microglial cells and determined the cell viability and specific cellular iron contents after 6 
h of incubation. As expected, the viability of the IONP-treated cells was compromised in 
a concentration-dependent manner (figure 1a). While microglial cells incubated without 
IONPs maintained a high cellular LDH activity and a high MTT reduction capacity 
during the 6 h of incubation, the presence of 3 mM iron in form of IONPs significantly 
lowered the cellular LDH activity (figure 1a, table 2) and the cellular MTT reduction 
capacity (table 2) to around 50% of the values determined for control cells. In addition, 
microglial cultures exposed for 6 h in the absence of IONPs did not contain cells which 
were stained by the membrane-impermeable fluorescent dye PI (figure 2b) and hardly 
any cells characterized by elevated ROS formation (figure 3b, figure 4b). In contrast, most 
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cells in microglial cultures that had been incubated with 3 mM IONPs were positive for 
PI (figure 2l) and ROS (figure 3l, figure 4d).  
The incubation of microglial cultures with IONPs was accompanied by a concentration-
dependent increase in the specific cellular iron content from 55 ± 44 nmol/mg protein of 
untreated cultures (n = 4) to around 1000 and 2500 nmol/mg for cells that had been 
exposed to 1 mM and 3 mM IONPs, respectively (figure 1b). 
3. Comparison of the effects of iron oxide nanoparticles on different types of brain cell 
cultures  
To compare microglial cells with other types of brain cells regarding the consequences of 
an exposure to IONPs, primary cultures of astrocytes and neurons were incubated with 
IONPs under experimental conditions that were identical (with the exception of the 
essential presence of additional 25 mM KCl in the GCM for neurons) to those applied 
for microglial cells. In contrast to microglial cells, the presence of IONPs in 
concentrations of up to 3 mM did neither lower the cellular LDH activity of cultured 
astrocytes and neurons (figure 1a,c) nor did it cause any severe increase in the cellular 
ROS production (figure 4h,l).  
Incubation of cultured astrocytes or neurons with IONPs caused a concentration-
dependent increase in the cellular iron contents (figure 1b). After 6 h incubation with 
IONPs in concentrations of 0.1 mM or 0.3 mM, the specific cellular iron contents were 
significantly lower in astrocytes and neurons compared to the respective values 
determined for microglial cultures while the iron contents did not significantly differ 
between the three types of neural cell cultures after incubations with 1 mM or 3 mM 
IONPs (figure 1b). Direct correlation of the cellular LDH activity to the specific cellular 
iron content confirmed that the loss in microglial viability was almost proportional to the 
increase in specific cellular iron content while no cellular LDH loss was observed from 
IONP-treated astrocytes or neurons, despite of similar high specific iron contents in all 
three types of neural cell cultures after exposure to millimolar concentrations of IONPs 
(figure 1c). 
4. Cellular localization of fluorescent IONPs in cultured brain cells 
Fluorescence microscopy was used to investigate the cellular localization of accumulated 
fluorescent IONPs. As application of millimolar concentration of fluorescent IONPs 
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caused toxicity in microglia, the neural cell cultures were incubated for 6 h with only 0.1 
mM IONPs and subsequently stained with lysotracker. Fluorescence microscopy revealed 
for all three types of IONP-treated neural cultures dotted fluorescence patterns for both 
BP-labeled IONPs and lysotracker (figure 5). However, the cellular distribution of 
fluorescence differed strongly between the culture types. In cultured microglial cells the 
majority of IONP fluorescence was found co-localized with lysotracker and displayed a 
mainly perinuclear staining (figure 5a-d). In contrast, in astrocytes (figure 5e-h) or neurons 
(figure 5i-l) at best little co-localization of IONP fluorescence and lysotracker was 
observed. IONPs were localized near the nucleus in cultured astrocytes (figure 5e-h) while 
the small somata of neurons do not allow conclusions on potential perinuclear 
localization of IONPs in cultured neurons (figure 5i-l). 
 
5. Mechanism of IONP-mediated toxicity to microglia 
Lysosomal localization of IONPs (figure 5a-d) as well as the increased ROS formation 
(figure 3l, 4d) and compromised viability (figure 1b, 2l) of IONP-treated microglial cells 
suggests that rapid iron liberation from IONPs in lysosomes and subsequent iron-
mediated ROS formation are involved in the observed IONP-mediated microglial 
toxicity. To test for this hypothesis, microglia were treated with NH4Cl or the vacuolar H+-
ATPase inhibitor Bafilomycin A1 to neutralize lysosomes (Poole and Ohkuma, 1981; 
Teplova et al., 2007) and thereby preventing the release of iron ions from the 
nanoparticles. Alternatively, the cells were incubated with 2,2’-bipyridyl to chelate the 
ferrous iron ions released from IONPs (Hohnholt et al., 2010). As a control for potential 
iron-independent effects of the chelator, also the non-chelating isomer 4,4’-bipyridyl was 
applied as control substance.  
Microglia were treated in presence and absence of 3 mM IONPs for 6 h with the above 
mentioned compounds and the cell viability was investigated by determination of cellular 
LDH activity and MTT reduction capacity (table 2) as well as by PI (figure 2) and ROS 
staining (figure 3). None of the compounds applied to modulate IONP-induced toxicity 
altered significantly the specific cellular iron content of microglial cells after incubation for 
6 h with 3 mM IONPs (table 2). In the absence of IONPs, incubation for 6 h with 
NH4Cl, Bafilomycin A1, 2,2’-bipyridyl or 4,4’-bipyridyl did not cause any loss in cellular 
LDH or MTT reduction capacity (table 2) nor was any staining of PI-permeable (figure 
2d,f,h,j) or ROS-positive (figure 3d,f,h,j) microglial cells observed. The H33342 staining 
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demonstrated that none of the conditions used lowered obviously the number of cells 
attached to the cell culture dish (figures 2, 3). 
Exposure of microglial cells to 3 mM IONPs caused a loss in cellular LDH activity by 
around 50% which was completely prevented by the presence of NH4Cl, Bafilomycin A1 
or the iron chelator 2,2’-bipyridyl while the non-chelating 4,4’-bipyridyl did not rescue 
microglial cells from IONP-induced loss in cellular LDH activity (table 2). Also the 
substantial IONP-induced loss in microglial MTT reduction capacity was prevented by 
the presence of NH4Cl and at least partially prevented by the presence of Bafilomycin A1 
or 2,2’-biypyridyl, whereas application of 4,4’-bipyridyl did not rescue the MTT reduction 
capacity of IONP-treated microglial cells (table 2). PI-staining of IONP-treated microglial 
cells (figure 2) confirmed the results obtained on LDH loss and MTT reduction capacity 
of IONP-treated microglial cells (table 2). While nearly all nuclei in microglial cultures 
were PI-positive after incubation with 3 mM IONPs (figure 2l), hardly any PI-positive 
cells were found if the cells were incubated with IONPs in the presence of NH4Cl, 
Bafilomycin A1 or 2,2’-biypyridyl (figure 2n,p,r). In contrast, presence of 4,4’-bipyridyl 
did not lower the number of PI-positive cells in IONP-treated microglial cultures (figure 
3t). Also the strong ROS-staining observed for IONP-treated microglial cells (figure 3l) 
was completely prevented by the presence of Bafilomycin A1 (figure 3n) and at least 
partially prevented by NH4Cl and 2,2’-bipyridyl (figure 3p,r) while presence of 4,4’-
bipyridyl hardly affected ROS-staining of IONP-treated cells (figure 3t). 
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Figure 1 Cell viability and iron accumulation in IONP-treated cultured microglial cells, 
astrocytes and neurons. The cultures were incubated with the indicated concentrations of 
IONPs for 6 h and the cellular LDH activity (a) and the specific cellular iron content (b) 
were determined. In panel c, the cellular LDH activity is plotted against the respective 
cellular iron content. The data represent means ± SD of results obtained in five to twelve 
(microglia) or three (astrocytes, neurons) experiments on individually prepared cultures. 
The 100% values for the cellular LDH activity of microglial cells, astrocytes and neurons 
are 505 ± 163 nmol/(min x mg) (n=20), 402 ± 81 nmol/(min x mg) (n=3) and 718 ± 215 
nmol/(min x mg) (n=3), respectively. Asterisks indicate significant differences of data 
compared to the respective control (incubation without IONPs) for one type of neural 
culture (*p<0.05, ***p<0.001). Significant differences of data obtained for astrocytes or 
neurons to those recorded for microglial cells are indicated by hashes (#p<0.05, ##p<0.01, 
###p<0.001).  
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Figure 2 Propidium iodide staining of IONP-treated microglia. Microglia were incubated 
for 6 h without (a-j) or with 3 mM IONPs (k-t) in the absence (a,b,k,l) or the presence of 
100 nM Bafilomycin A1 (c,d,m,n), 10 mM NH4Cl (e,f,o,p), 100 μM 2,2’-bipyridyl (g,h,q,r) 
or 100 μM 4,4’-bipyridyl (I,j,s,t). After the subsequent 15 min incubation with propidium 
iodide (PI) and H33342, cell with impaired membrane integrity were PI-positive, while 
the nuclei of all cells present are indicated by H33342-staining . The scale bar in panel t 
refers to 100 μm and applies to all panels. 
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Figure 3 Staining of reactive oxygen species in IONP-treated microglia. Microglia were 
incubated for 6 h without (a-j) or with 3 mM IONPs (k-t) in the absence (a,b,k,l) or the 
presence of 100 nM Bafilomycin A1 (c,d,m,n), 10 mM NH4Cl (e,f,o,p), 100 μM 2,2’-
bipyridyl (g,h,q,r) or 100 μM 4,4’-bipyridyl (i,j,s,t) before the cells were incubated for 15 
min with dihydrorhodamine to test for ROS generation. The nuclei of all cells present 
were visualized by H33342. The scale bar in panel t refers to 100 μm and applies to all 
panels. 
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Figure 4 Staining of reactive oxygen species in IONP-treated neural cell cultures. Primary 
microglia, astrocytes and neurons were incubated without (a,b,e,f,i,j) or with 3 mM 
IONPs (c,d,g,h,k,l) for 6 h before the cells were incubated for 15 min with 
dihydrorhodamine to test for ROS generation. The nuclei of all cells present were 
visualized by H33342. The scale bar in panel l represents 100 μm and applies to all 
panels.  
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Figure 5 Localization of fluorescent IONPs in cultured neural cells. Microglial cells (a-d), 
astrocytes (e-h) and neurons (i-l) were incubated with 0.1 mM IONPs  for 6 h followed by 
an incubation with 100 nM lysotracker DND-99 for further 90 min. Cells were washed 
with PBS and fixed prior to monitoring by fluorescence microscopy for IONP 
fluorescence (a,c,i) and lysotracker fluorescence (b,f,j). The overlays of the IONP and 
lysotracker fluorescences (c,g,k) show co-localization of green IONPs and red lysotrackers 
in yellow. The scale bar in l represents 25 μm and applies to all panels. Full color images 
can be found in the online version of the article. 
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Table 1 Physicochemical properties of IONPs 
    hydrodynamic  polydispersity ζ-potential 
  [IONP] diameter (nm) index (mV) 
H2O 1 mM  44 ± 2 0.190 ± 0.017 -39 ± 8 
3 mM  47 ± 2 0.186 ± 0.031 -50 ± 3 
GCM 1 mM  90 ± 15*** 0.297 ± 0.029** -10 ± 4** 
  3 mM  158 ± 28**,## 0.263 ± 0.025* -10 ± 2*** 
 
Asterisks indicate significant differences between dispersion of IONPs in glia conditioned 
medium (GCM) and water (*p<0.05, **p<0.01, ***p<0.001) and hashes between 1 and 3 
mM IONPs (##p<0.01). Measurements were performed thrice with different batches of 
IONPs.  
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Discussion 
Application of IONPs has previously been reported to compromise the viability of 
cultured microglial cells (Jenkins et al., 2013; Luther et al., 2013; Pickard and Chari, 
2010). This vulnerability was confirmed for microglial cells treated with fluorescent 
DMSA-coated IONPs as demonstrated by a loss of cellular LDH activity and MTT 
reduction capacity as well as by increased permeability of the cell membrane for PI. The 
increase in cellular ROS-staining suggests that iron-catalyzed radical formation is involved 
in the damage caused by IONPs to microglial cells as previously also shown for 
peripheral macrophages and other cell types (Hanini et al., 2011; Dwivedi et al., 2014; 
Lee et al., 2014). The most likely pathway involved in the ROS generation and toxicity in 
IONP-treated microglial cells involves endocytotic uptake of IONPs, lysosomal 
degradation of IONPs to iron ions, iron-catalyzed ROS formation by the Fenton reaction 
and oxidative cell damage, as previously suggested (Jenkins et al., 2013; Luther et al., 
2013).  
Endocytotic uptake of IONPs and trafficking of the internalized IONPs to the lysosomal 
compartment have previously been demonstrate for cultured microglial cells (Luther et 
al., 2013) and was confirmed for the conditions used here by the co-localization of 
fluorescent IONPs with lysotracker in microglial cells. The ability of NH4Cl and 
Bafilomycin A1 which neutralize the lysosomal pH by diffusion of ammonia to the acidic 
lysosome (Poole and Ohkuma, 1981) and by inhibition of the lysosomal proton pump 
(Teplova et al., 2007), respectively, to lower or even prevent ROS formation and cell 
toxicity in IONP-treated microglial cells demonstrates that the low pH of lysosomes is 
involved in the IONP-induced microglial toxicity. This is consistent with literature data 
from cell-free experiments showing that iron ions are liberated from IONPs at lysosomal 
pH (Levy et al., 2010; Malvindi et al., 2014). Also the presence of reducing substances 
such as glutathione in lysosomes (Kurz et al., 2010) may accelerate the liberation of iron 
ions from the IONPs and also helps to maintain iron in the ferrous state which is 
required for export from the acidic compartment into the cytosol by the divalent metal 
transporter 1 (Lawen and Lane, 2013). This transporter has been reported to be 
expressed in microglial cells (Rathore et al., 2012; Urrutia et al., 2013). Thus, rapid 
lysosomal liberation of internalized IONPs in microglial cells is likely to generate large 
amounts of ferrous iron which causes ROS formation and cell damage. This view is 
strongly supported by the ability of the membrane permeable ferrous iron chelator 2,2’-
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bipyridyl, but not its non-chelating analog 4,4’-bipyridyl (Kinnunen et al., 2002; Ma et al., 
2006), to lower ROS generation and prevent toxicity in IONP-treated microglial cells. 
The residual ROS formation in microglial cells in the presence of 2,2’-bipyridyl might 
result from ROS production on the IONP-surface (Voinov et al., 2011) as the Fe2+-2,2’-
bipyridyl complex is not Fenton reactive (Pierre and Fontecave, 1999). However, 
microglial cells appear to cope with a low rate of ROS production found under such 
conditions as their high antioxidative potential (Dringen, 2005; Hirrlinger et al., 2000) is 
likely to protect the cells against toxicity by a moderate amount of ROS.  
Cultured astrocytes and neurons accumulated similar amounts of IONPs under the 
conditions used. The specific iron contents determined were in the range of values 
previously reported for these cultures in serum-containing media (Geppert et al., 2011; 
Geppert et al., 2013; Petters and Dringen, 2015). Comparison of microglial cultures with 
astrocytes and neurons revealed that microglial cells accumulated IONPs more efficiently 
when the different types of cultures were treated with low concentrations of 0.1 mM or 
0.3 mM IONPs as demonstrated by the 2- to 5-fold higher specific cellular iron contents 
in microglial cells. This stronger IONP accumulation by microglial cells is consistent with 
literature data for other types of IONPs (Jenkins et al., 2013; Pinkernelle et al., 2012). 
Different types of endocytotic pathways involved in IONP uptake are unlikely to explain 
the observed differences in IONP accumulation between the three types of neural cells 
investigated as in serum-containing media clathrin-mediated endocytosis and 
macropinocytosis have been reported to mediate IONP uptake into both cultured 
microglial cells and astrocytes (Geppert et al., 2013; Luther et al., 2013) while neurons 
appear to take up IONPs predominantly by clathrin-mediated endocytosis (Petters and 
Dringen, 2015). However, as microglia are the "phagocytotic cells" in the brain and as 
microglial cells, but not astrocytes and neurons, have the prominent function to 
incorporate and digest cell debris from their environment (Eyo and Dailey, 2013; Nayak 
et al., 2014), microglial cells are likely to be equipped with a strong endocytotic transport 
capacity which could explain the higher efficiency of microglial cells to accumulate iron 
from low concentrations of IONPs. For incubations with 3 mM IONPs similar specific 
iron contents were determined for all three types of neural cultures. However, this 
apparent inability of microglial cells to accumulate more IONPs than astrocytes and 
neurons under these conditions is likely to be a direct consequence of the developing 
microglial toxicity which will impair IONP accumulation while astrocytes and neurons 
remained viable during the incubation and continued to accumulate IONPs.  
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The relative resistance of astrocytes and neurons towards high concentrations of IONPs is 
most likely caused by a slow transfer of internalized IONPs into the lysosomal 
compartment which is required for liberation of iron ions from IONPs. This view is 
supported by the apparent absence of a co-localization of fluorescent IONPs with 
lysotracker in IONP-treated cultured astrocytes and neurons. In contrast, IONP-treated 
microglial cultures showed under identical conditions strong co-localization of fluorescent 
IONPs with lysotracker. Thus, a more rapid internalization and lysosomal degradation of 
IONPs to ROS-generating iron ions in microglial cells is likely to cause the severe toxicity 
observed for this cell type after exposure to IONPs. Such processes appear to be slower 
in astrocytes and neurons, explaining the relative resistance of these cell types against 
potential IONP-induced toxicity (Geppert et al., 2012; Geppert et al., 2011; Geppert et 
al., 2013; Petters and Dringen, 2015). However, also astrocytes and neurons have the 
potential to slowly liberate iron from accumulated IONPs. At least for other experimental 
conditions some ROS formation has been reported for IONP-treated astrocytes and 
neurons (Geppert et al., 2012; Petters et al., 2014b) and depending on the type of IONPs 
applied and the incubation conditions used also delayed toxicity was observed for these 
cell types (Sun et al., 2013; Rivet et al., 2012; Petters and Dringen, 2015). 
  
Conclusions 
In the present study we show that microglia are more susceptible to IONP exposure as 
astrocytes and neurons which is likely to be caused by fast lysosomal iron liberation from 
IONPs in microglial cells which causes severe iron-mediated ROS production and 
oxidative cell damage. This suggests that also in vivo microglia may be harmed more 
strongly by IONPs than other brain cells. However, microglial toxicity in brain as 
consequence of an IONP exposure is likely to depend on the route which mediates entry 
of IONPs into the brain. Little harm to microglial cells is expected, if IONPs are applied 
to the blood, e.g. as MRI contrast agent, as IONPs which pass the intact BBB via 
transcytosis (Yan et al., 2013) encounter astrocytes. These cells cover almost completely 
the brain capillaries (De Bock et al., 2014) and have at least in culture the capacity to 
accumulate large amounts of IONPs without being damaged by the accumulated IONPs 
(Geppert et al., 2012; Jenkins et al., 2013; present study). In contrast microglial cells are 
very likely to encounter blood-derived IONPs, if the BBB is damaged by injury or tumors 
(Nayak et al., 2014). For such conditions predominantly microglial cells have been 
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reported to take up IONPs (Neuwelt et al., 2004; Taschner et al., 2005). Also intranasal 
application of IONPs (Wang et al., 2011) as well as direct injection of IONPs into brain 
tumors for magnetic fluid hyperthermia (van Landeghem et al., 2009) establish direct 
contact of microglial cells with IONPs which causes microglial IONP accumulation and 
microglial activation (Wang et al., 2011). Such an IONP-induced activation of microglial 
cells might result in neurotoxicity (Correale, 2014). However, IONP-induced microglial 
toxicity which will lower the number of these cells and will subsequently also impair the 
neuroprotective functions of microglia in brain including the defense against pathogens 
and the support in repair processes (Kettenmann et al., 2011; Nau et al., 2014). For such 
conditions, strategies to prevent the fast IONP internalization, the liberation of iron ions 
from internalized IONPs and/or iron-mediated ROS production should be considered in 
order to prevent IONP-induced microglial toxicity.  
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3.  Summarizing discussion 
Dimercaptosuccinate (DMSA)-coated IONPs have been frequently used to study 
accumulation and biocompatibility of IONPs on neural cells in vitro (Geppert et al., 
2011; Geppert et al., 2012; Geppert et al., 2013; Hohnholt et al., 2010; Hohnholt and 
Dringen, 2011; Hohnholt et al., 2011) and in vivo (Mejias et al., 2010; Mejias et al., 2013) 
but their cellular localization could not be monitored by light microscopy. To overcome 
this problem, fluorescent versions of DMSA-coated IONPs were synthesized, 
characterized, compared to non-fluorescent DMSA-coated IONPs and applied to cell 
culture models of the four major brain cell types to investigate and compare uptake 
capacities and potential adverse consequences of an IONP exposure of different types of 
brain cells.  
 
3.1. Synthesis and characterization of fluorescently labeled iron 
oxide nanoparticles 
The preparation of fluorescently labeled IONPs was a three-step process: i) the bare 
maghemite NPs were synthesized by an alkaline co-precipitation of ferrous and ferric salts 
(Geppert et al., 2009), ii) the coating material DMSA was labeled at alkaline conditions 
with the fluorescent dye BODIPY (BP) by coupling thiol groups of DMSA with the thiol-
reactive iodoacetamide function of BP, forming a thioether (Kaltz, 2011), and iii) coating 
of IONPs at pH 3 with BP-DMSA (chapters 2.2 and 2.3). The initial method for 
fluorescence labeling of DMSA was introduced by Felix Bulcke in a research project in 
2011.  
For this thesis project, three versions of BP-labeled IONPs were prepared which differed 
in the amounts of BP used and in the numbers of coating steps (Table 3.1). For labeling, 
DMSA and BP were mixed in a molar ratio of 1:0.03 (BP-IONPs) or 1:0.15 (BP(5x)-
IONPs). Thus, either 1.5% or 7.5% of the total number of thiol groups in the DMSA 
used for coating was modified with BP. BP(5x)-IONPs were also surrounded with a 
second layer of pure DMSA, resulting in D-BP(5x)-IONPs. Non-labeled DMSA-coated 
IONPs are referred to as D-IONPs.  
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3.1.1. Characterization of BODIPY-labeled iron oxide nanoparticles  
After coating, single IONPs were spherical with a diameter of 4-20 nm. They displayed a 
clear crystalline structure seen by electron microscopy (chapters 2.2 and 2.3) as reported 
previously for D-IONPs (Geppert et al., 2011). Moreover, the synthesized IONPs 
possessed the for superparamagnetic properties characteristic for IONPs as demonstrated 
by a strong magnetization on application of a magnetic field but the absence of 
remanescence after removal of the magnetic field (chapter 1.3).  
When dispersed in media, IONPs form small aggregates. The initially synthesized IONPs 
had hydrodynamic diameter of 60 nm and a ζ-potential of around -50 mV when 
dispersed in water (chapters 2.2-2.4) as previously described (Geppert et al., 2011) 
whereas later preparations generated reproducibly smaller IONPs of around 30 nm with 
the same ζ-potential (chapter 2.5). The reason for this is unclear but slight variations 
between the initial and later syntheses might have caused these alterations. The used 
experimental set up did not allow very controlled conditions to achieve exact pH values 
and temperatures between the syntheses. Indeed, the alkaline co-precipitation method is 
described as simple and effective to generate large volumes of IONP dispersions but has 
the disadvantage of generating IONPs of a broad size distribution since already slight 
variations of the preparation conditions such as pH, temperature, iron salt species or ratio 
of ferrous to ferric ions strongly affect the outcome of the IONP synthesis (Massart, 1981; 
Gnanaprakash et al., 2007; Hasany et al., 2012). 
 
3.1.2. Fluorescent properties of BODIPY-labeled iron oxide nanoparticles 
The labeling of DMSA with BP prior to coating was successful as confirmed by 
fluorescence and mass spectrometry as well as by energy dispersive X-ray spectroscopy 
(chapters 2.2 and 2.3; Kaltz, 2011). The fluorescence of BP-labeled IONPs depends on 
the amount of BP within the coat but also on the pH and on presence of uncoated 
IONPs which caused quenching (Kaltz, 2011). By lowering the pH, the intensity of BP-
fluorescence is decreased. Since this was not seen in BP-DMSA solution alone (data not 
shown), IONPs mediate this pH effect probably by IONP destabilization with higher 
proton concentration since also precipitated BP-IONPs had strongly decreased 
fluorescence (data not shown). Moreover, fluorescence intensities of lysates of OLN-93 
cells after incubation at 37°C were similar to those after incubation at 4°C although the 
iron contents differed by a factor of two (unpublished data). The pH-dependent 
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modulation of BP-labeled IONP fluorescence has to be considered for analysis of BP-
IONP uptake by fluorescence microscopy as fluorescence of BP-labeled IONPs within 
acidic compartments might underestimate and not represent the real amount of BP-
labeled IONPs in these compartments.  
Since the fluorescence of BP(5x)- and BP-IONPs principally co-localized with staining for 
iron in microglial cells (chapter 2.3) and OLN-93 cells (data not shown), respectively, 
these fluorescent IONPs are considered as suitable as tool for visualization of IONPs in 
cells. However, also non-dotted BP-fluorescence occurred outside from IONP-containing 
vesicles, e.g. in the nucleus, which hinds towards a liberation of the coat over time in 
endosomal/lysosomal environments with low pH and reducing conditions and/or towards 
free dye in the IONP dispersion. This elution of fluorescent dye was reported previously 
for N-isopropylacrylamide NPs containing rhodamine B under cell-free conditions as well 
as after exposure to A49 cells (Tenuta et al., 2011). Although BP-IONPs were washed 
once after coating, the presence of a residual amount of unbound coating material cannot 
be fully excluded. This might explain some variations in non-vesicular stainings in BP- 
and BP(5x)-IONP-treated cells irrespective of cell type, incubation medium and time 
(data not shown).  
 
3.1.3. Stability of BODIPY-labeled iron oxide nanoparticles  
The knowledge on stability of IONPs in physiological media is fundamental for 
applications. Hence, the stability of IONPs in dispersion was investigated by 
determination of the hydrodynamic diameter and the ζ-potential which correspond to size 
and charge of IONPs, respectively (Table 3.1; chapters 2.2-2.5). These two parameters 
are most crucial for interaction of NPs with bio-interfaces (Nel et al., 2009) and depended 
on the media used for dispersion. Table 3.1 lists for the non-fluorescent and the three 
versions of BP-labeled IONPs the hydrodynamic diameter and ζ-potential in various 
media before and after contact to cells.  
All four types of IONPs were colloidally stable in water as seen by a hydrodynamic 
diameter between 50-70 nm and a ζ-potential of -50 to -66 mV (Table 3.1). The increased 
diameter of the modified IONPs compared to the non-fluorescent D-IONPs might be 
caused by the different coating procedure. D-IONPs were prepared by solving DMSA 
resulting in an acidic solution to which IONPs were added and stirred for coating. In 
contrast, the BP-DMSA solution was in an alkaline buffer and was acidified after IONP 
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application. Moreover, the batch scales differed strongly for synthesis of D-IONPs and 
BP-labeled IONPs. While IONPs were coated with DMSA in a larger volume of around 
100 mL, BP-labeled IONPs had to be prepared in small batches of around 1 mL to 
establish better reproducibility.  
Presence of salts such as in incubation buffer (IB) did not affect size of D- and BP-IONPs 
but the charge was altered towards less negative values (Table 3.1) which might be caused 
by binding of cations to the carboxylate groups of DMSA. While in water dispersions the 
introduction of BP into the coat had only marginal effects on the hydrodynamic diameter, 
the stability of IONPs in IB depended strongly on the amount of dye within the coat. 
BP(5x)-IONPs which had a 5-fold higher BP content than BP-IONPs agglomerated in 
serum-free IB which was prevented by a second coat of DMSA (D-BP(5x)-IONPs) 
though also D-BP(5x)-IONPs tend to aggregate (Table 3.1). D-IONPs are stabilized due 
to formation of a DMSA cage generated by disulfide bridges between the molecules 
(Fauconnier et al., 1997). The prevention of disulfide bridges between DMSA molecules 
due to binding of BP as well as the steric hindrance by the dye probably result in a 
destabilization of the coat when a certain amount of SH-groups is modified and hence, 
leads to the observed destabilization of BP(5x)- and D-BP(5x)-IONPs. Thus, BP-IONPs 
which contain only 1.5% BP in the coat are suitable for applications in IB under serum-
free conditions but not BP(5x)-IONPs or D-BP(5x)-IONPs. All four types of IONPs 
agglomerated in DMEM without serum (Table 3.1) most likely due to presence of 
destabilizing compounds such as phosphate (Dr. Mark Geppert, personal 
communication). 
Presence of 10% serum in physiological media caused the formation of a protein corona 
around IONPs and thereby drastically changed interactions between NPs, as expected 
(Nel et al., 2009). Hence, fluorescent and non-fluorescent IONPs aggregated in presence 
of serum to agglomerates of around 160 nm (Table 3.1) or 80 nm (chapter 2.5) 
diameters, dependent on IONP batches and concentration, and IONPs possessed a ζ-
potential of -10 mV as described previously (Geppert et al., 2013). While D-, BP- and 
BP(5x)-IONPs were very similar in size, D-BP(5x)-IONPs were significantly larger (Table 
3.1). Binding of proteins towards D-IONPs is probably mediated by ionic interaction and 
perhaps by disulfide bridges between DMSA and proteins. Although a protein corona 
masks the actual nature of NPs (Monopoli et al., 2012), the composition of the corona 
might depend on the coat as reported for IONPs with various coatings (Jedlovszky-Hajdu 
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et al., 2012). Since introduction of BP into the coat might change possible interactions 
between proteins and coat, the composition of the proteins attached to IONPs might 
differ in absence and presence of BP. However for D-IONPs and BP-IONPs, no altered 
physicochemical properties and uptake by OLN-93 were observed (chapter 2.2) 
suggesting no substantial differences between D- and BP-IONPs in the interaction 
between protein corona and cell surface. 
Contact to OLN-93 cells led to an increased hydrodynamic diameter of the four types of 
IONPs when dispersed in IB in absence of serum (Table 3.1) most likely because of 
compounds released from cells stimulate agglomeration as reported previously at least for 
primary astrocytes (Geppert et al., 2013). While D- and BP-IONPs remained stably 
dispersed, D-BP(5x)-IONPs agglomerated after contact with cells (Table 3.1), 
strengthening the trend to stronger aggregation seen prior to incubation. In the presence 
of serum, contact to cells did not result in a destabilization of IONPs but rather lowered 
the average hydrodynamic diameter (Table 3.1) which may be a consequence of cellular 
uptake of larger aggregates during incubation with IONPs.  
Importantly, BP-IONPs possessed the same characteristics in morphology, size of single 
NPs (chapter 2.2), hydrodynamic diameter and ζ-potential compared to D-IONPs (Table 
3.1). BP-IONPs are accumulated by OLN-93 cells to similar amounts as D-IONPs and 
by the same mechanism (chapter 2.2). Hence, BP-IONPs are suitable as fluorescent 
version of D-IONPs to investigate localization of D-IONPs within cells for both serum-
free and serum-containing conditions. In the presence of serum, also BP(5x)-IONPs have 
similar characteristics as D-IONPs and can be considered as tool to study uptake and 
cellular localization of D-IONPs with the advantage of higher fluorescent signals of 
BP(5x)-IONPs compared to BP-IONPs.  
 
3.2. Uptake and effects of iron oxide nanoparticles in cultured 
brain cells 
Fluorescent and non-fluorescent versions of DMSA-coated IONPs were studied in this 
thesis for uptake and potential adverse effects on cell culture models of brain cells. The 
most important results obtained for such IONPs on neural cell cultures from this thesis 
or reported in literature are compared in Table 3.2. Important in this context is that the 
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presence of BP within the coat had no influence on the physicochemical properties and 
cellular accumulation of D-IONPs (chapter 2.2; Table 3.1). 
 
3.2.1. Accumulation of iron oxide nanoparticles by cultured brain cells 
Comparable concentrations of IONPs and incubation conditions resulted in maximal 
iron contents that were similar between astrocytes, microglia and neurons while OLN-93 
cells seemed to have a lower accumulation capacity (Table 3.2). Also exposure to other 
types of IONPs resulted in similar iron contents in cultured astrocytes and neurons (Sun 
et al., 2013). Concerning microglia, it should be considered that maximal iron contents 
were determined for at least partially toxic conditions whereas viable microglia were more 
efficient in IONP accumulation compared to astrocytes and neurons (chapter 2.5), 
supporting literature data (Pinkernelle et al., 2012; Jenkins et al., 2013). In general, 
exposure to IONPs in the absence of serum in the incubation medium resulted in higher 
specific cellular iron contents of neural cell cultures compared to serum-containing 
conditions at least for astrocytes, neurons and OLN-93 cells (chapters 2.2 and 2.4; 
Geppert et al., 2013) while no data could be obtained for primary microglia under serum-
free conditions due to some toxicity (Dr. Eva M. Luther, personal communication). 
IONP accumulation by all investigated cultured brain cells slowed down with extended 
incubation time (chapter 2.4; Hohnholt and Dringen, 2011; Geppert et al., 2013). 
Differences in uptake kinetics between types of cultured brain cells might result from 
diversity in protein or lipid composition of the cell membranes or expression of proteins 
involved in endocytosis such as members of the small GTPase Rab family which are 
differentially expressed in neurons and glia (Ng and Tang, 2008; DeKroon and Armati, 
2001). The decreasing velocity of IONP uptake over time might result from a change in 
coat/corona due to secretion of biomolecules by cells which was recently reported for 
gold NPs exposed to several cell lines (Albanese et al., 2014) or from alterations in lipid 
and protein composition of the membrane over time due to binding and uptake of 
IONPs (Dawson et al., 2009; Wu et al., 2013b), thereby changing requirements for 
endocytotic pathways. Moreover, the uptake process of IONPs might be down-regulated 
and/or IONPs or iron liberated from internalized IONPs may be exported though no 
export of iron was observed at least in cultured astrocytes which were loaded with IONPs 
and incubated 7 d in IONP-free medium (Geppert et al., 2012). 
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Figure 3.1 Uptake and effects of IONPs in cultured brain cells. IONPs are 
taken up in presence of serum (protein corona) via clathrin-mediated 
endocytosis (all cell types) and macropinocytosis (astrocytes, microglia, 
oligodendroglial cells) whereas in absence of serum the pathway for uptake 
is unknown. The identity of intracellular IONP-containing vesicles is 
unknown for neurons, astrocytes and oligodendrocytes whereas in microglia 
IONPs are localized in lysosomes. IONPs differ in their toxic potential on 
the four cell types. Acute exposure of IONPs causes cell death in microglia 
due to Fe2+-mediated ROS but not in the other cell types whereas delayed 
toxicity was observed in neurons. Astrocytes and oligodendroglial cells store 
the iron released from internalized IONPs in ferritin and are only 
transiently exposed to some ROS.  
 
Immunocytochemical staining for astrocytic markers (glutamine synthetase (GS) and glial 
fibrillary acidic protein (GFAP)) after treatment with BP-IONPs revealed stronger BP 
staining in GS-positive than in GFAP-positive cells in astrocyte cultures (Figure 3.2). 
However, a decreased GFAP expression in astrocytes did not lead to a significantly 
increased accumulation of IONPs (chapter 2.1). Thus, besides differences between 
neural cell types, there were alterations among individual types of astrocytes in one 
culture which may reflect the heterogeneity of astrocytes in brain (chapter 2.1; Zhang and 
Barres, 2010; Oberheim et al., 2012; Bayraktar et al., 2014). 
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Figure 3.2 IONP accumulation by GFAP- and GS-positive astrocytes. 
Primary cultures of astrocytes were incubated with 0.5 mM BP-IONPs in 
incubation buffer (see chapters 2.1 and 2.2) for 4 h at 37°C. After 
incubation, cells were washed thrice with cold phosphate-buffered saline, 
fixed with 3.5% (w/v) paraformaldehyde and stained for glial fibrillary acidic 
protein (GFAP; a,c) or glutamine synthetase (GS; b,d) as described in 
chapter 2.1. The overlay of BP fluorescence and Cy3-labeled secondary 
antibody is depicted in yellow. The scale bar in b represents 50 μm and 
applies for panels a and b, the scale bar in d represents 20 μm and applies to 
panels c and d.  
 
3.2.2. Uptake of iron oxide nanoparticles in serum-free media 
In cultured astrocytes, IONPs were intracellularly localized in vesicles as shown by 
electron microscopy (Geppert et al., 2012; Geppert et al., 2011). This suggests that one or 
more endocytotic processes are involved. Endocytosis has been divided into phagocytosis 
for large particles and pinocytosis which is further subdivided in macropinocytosis, 
clathrin-mediated and clathrin-independent endocytosis (Canton and Battaglia, 2012). 
The latter pathway is far less understood than the formers but is described to require 
cholesterol and to be mediated by caveolin, ADP-ribosylation factor 6, RhoA or flotillin 
(Blouin, 2013; Maldonado-Baez et al., 2013). Depending on the mechanism and proteins 
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involved in the invagination, also the generated endosomes vary in size and shape, such as 
spherical or tubular, between the different pathways and such endosomes might traffic 
differently within the cell (Blouin, 2013; Canton and Battaglia, 2012; Doherty and 
McMahon, 2009). One commonly used approach to test for pathways responsible for 
IONP uptake is application of inhibitors although such inhibitors target more or less 
specifically a given endocytotic pathway (Ivanov, 2008). 
For none of the cell culture models of brain cells used, the uptake mechanism for IONPs 
in absence of serum was identified. There are several options why IONP uptake was not 
inhibited in absence of serum such as rapid switch to other pathways (Doherty and 
McMahon, 2009) or the involvement of a pathway for which the inhibitors used were not 
useful. Furthermore, a vesicle-forming but non-endocytotic pathway might contribute to 
the IONP uptake by solely physical processes. At least for silica NPs it was reported that 
endocytotic proteins are not necessary for uptake. These NPs are internalized into 
endocytosis-incapable red blood cells by mediating deformation and invagination of 
membrane because of adhesive forces between NPs and membrane (Zhao et al., 2011). 
Such a process might be facilitated especially in the absence of a protein corona due to 
strong binding of the strongly charged IONPs to the cell surface. 
 
3.2.3. Uptake of iron oxide nanoparticles in serum-containing media 
In contrast to serum-free conditions in presence of 10% serum, endocytotic IONP uptake 
by the different cultured brain cells was mainly clathrin-mediated endocytosis and 
macropinocytosis (Table 3.2). Importantly, the inhibitors which were effective to inhibit 
IONP uptake varied between the cell types investigated (chapters 2.2-2.4; Geppert et al., 
2013) as well as between different types of IONPs. For cultured astrocytes Pickard et al. 
showed inhibition of uptake of carboxyl-modified SPHERO Nile Red fluorescent 
magnetic particles by tyrphostin 23, dynasore, amiloride and EIPA (Pickard et al., 2010) 
whereas D-IONP uptake was blocked by chlorpromazine and wortmannin (Geppert et 
al., 2013). Such a variation of the effectiveness of endocytosis inhibitors was also reported 
for polystyrene NPs in several cell lines (dos Santos et al., 2011). While the uptake of 
IONPs by oligodendroglial cells and cerebral granule neurons was inhibited completely 
by application of two or three endocytosis inhibitors (chapters 2.2 and 2.4), the uptake of 
IONPs by primary astrocytes and microglia could not be blocked to the level of the 4°C 
binding control suggesting the involvement of multiple pathways in IONP uptake. The 
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different neural cell types might express certain endocytotic pathways and/or some 
isoforms of proteins involved differently and hence, might strongly differ in their 
sensitivity to endocytosis inhibitors.  
In general, the accumulation of IONPs in presence of serum was lowered by 80-90% as 
compared to incubation without serum (chapters 2.2 and 2.4; Geppert et al., 2013). This 
is in accord with reports on other cell types and other types of NPs (Petri-Fink et al., 
2008; Lesniak et al., 2013). Likely, reason for this are the lower binding capacity of 
IONPs with protein corona to cell membranes compared to IONPs without a protein 
corona. At least for lung epithelial cells it was shown by atomic force microscopy that the 
detachment force per bond of IONPs to the cells as well as the number of bonds is 
higher for IONPs in serum-free media than in presence of 10% serum (Pyrgiotakis et al., 
2014). Moreover, the decreased iron content after incubation with IONPs in presence of 
serum might also be caused by the involvement of different endocytotic pathways under 
serum-free and serum-containing conditions.  
 
3.2.4. Cellular localization of iron oxide nanoparticles  
Cell associated IONPs are present extracellularly attached and intracellular after 
internalization. Incubations at 4°C are frequently used as binding control to investigate the 
amount of material attached extracellularly to the membrane (Kim et al., 2006; Geppert 
et al., 2011; Smith et al., 2012b). Except for microglia which displayed only 20% of total 
iron content as IONPs sticking to the cell surface, probably due to fast internalization of 
IONPs, all other investigated neural cell types contained after incubation at 4°C around 
50% of iron content as compared to incubations at 37°C irrespective of serum-free or 
serum-containing media. This implies lower binding of protein-coated IONPs to cell 
membranes compared to serum-free conditions (chapters 2.2 and, 2.4; Geppert et al., 
2013). Moreover, one should consider that at 4°C, compared to 37°C, Brownian 
movement is decreased (He and Hui, 1985) and that IONPs and components of the 
plasma membrane have decreased velocity and fluidity, respectively which in turn might 
lower the chance for interactions between IONPs and membrane. As recently described, 
also the composition of the protein corona depends on incubation temperature 
(Mahmoudi et al., 2013) and hence, different interactions of IONPs with the cell surface 
might be possible so that 4°C binding controls might not exclusively represent the cell 
adsorbed part of cellular IONPs in presence of serum. 
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After uptake, D- and BP-IONPs were found in vesicles in all neural cell types investigated 
(Table 3.2; Figure 3.1) as seen by fluorescence microscopy (chapters 2.2-2.5) or TEM 
(Geppert et al., 2011; Geppert et al., 2012) and resided mainly perinuclear (chapter 2.5), 
supporting literature data for secondary astrocytes and microglia, for the neuronal cell line 
PC12 and for OLN-93 cells (Pisanic et al., 2007; Pickard et al., 2010; Pickard and Chari, 
2010; Hohnholt et al., 2010; Jenkins et al., 2013). This suggests that IONP-containing 
vesicles are transported along microtubules as described for IONP-encapsulated silicon 
particles in human microvascular vein endothelial cells (Ferrati et al., 2010). Indeed, 
immunocytochemical staining for α-tubulin showed co-localization with BP-IONPs in 
secondary astrocytes as observed during a research project by Nimesha Tadepalle in 
2012. Only in microglia there was evident rapid lysosomal localization of the IONPs 
(Figure 3.1; chapters 2.3 and 2.5) suggesting different endosomal trafficking within the 
four neural cell types investigated. The fate of endosomes depends on the endocytotic 
pathway from which they derive. While phagosomes fuse directly with late endosomes or 
lysosomes, endosomes coming from macropinocytosis or from clathrin-, caveolin- or 
ADP-ribosylation factor 6-mediated endocytosis evolve first to early endosomes which are 
only slightly acidic (Doherty and McMahon, 2009). From early endosomes they can 
either traffic to late endosomes and lysosomes or be sorted to the Golgi apparatus or to 
recycling endosomes (Doherty and McMahon, 2009). Different intracellular trafficking of 
endosomes plays probably a role the observed for differences in intracellular localization 
of IONP-containing vesicles within cultured astrocytes, microglia and neurons. 
 
3.2.5. Toxic effects of an exposure of iron oxide nanoparticles to cultured brain cells 
Acute exposure of IONPs to cultured brain cells compromised microglial viability but not 
that of astrocytes, oligodendroglial cells and neurons (Table 3.2; Figure 3.1). The likely 
reason for this observation is the rapid transfer of IONP-containing vesicles to lysosomes 
in microglia, accompanied by a rapid liberation of iron ions from IONPs in acidic 
environments (chapter 2.5). The liberated Fenton-reactive ferrous iron causes extensive 
ROS generation and thereby cell death of microglia (chapter 2.5; Figure 3.1). In addition, 
these cells displayed a round shape (unpublished data) and clustering of cells (chapter 
2.5) suggesting a harmed cytoskeleton in IONP-treated microglia. An impairment of the 
cytoskeleton was shown for PC12 cells after IONP exposure by immunocytochemical 
staining (Soenen et al., 2011; Dadras et al., 2013) whereas the microtubule network at 
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least in secondary astrocytes was not altered after IONP treatment as observed during a 
research project by Nimesha Tadepalle in 2012.  
The slow acidification of IONP-containing vesicles in astrocytes, oligodendroglial cells 
and neurons protected them from acute damage by iron-induced oxidative stress. It 
seems that astrocytes are the neural cell type which is able to tolerate most IONPs 
(chapter 1.4). Recently it was shown that toxicity was only observed for astrocytes when in 
addition to IONP exposure an alternating magnetic field was applied which led to 
mechanical damage (Schaub et al., 2014).  
Delayed toxicity was observed for cultured neurons which were treated with IONPs 
followed by a 24 h IONP-free recovery period when neuronal iron contents were higher 
than 400 nmol/mg (chapter 2.4). For similar concentrations of carboxylated aminosilane 
coated IONPs, a decreased vitality in primary cortical neurons after 24 h was reported 
(Sun et al., 2013). Some ROS occurrence in neurons was seen after 6 h treatment with 
2 mM D-IONPs under serum-free conditions (chapter 1.4), suggesting that the observed 
delayed toxicity in cerebellar granule neurons (chapter 2.4) was probably mediated by 
ROS. However, it cannot be excluded that IONPs may cause changes in 
electrophysiological properties of neurons as previously reported for primary frontal 
cortex cell culture (Gramowski et al., 2010). In contrast to neurons, no delayed toxicity 
was reported for primary astrocytes even after 7 d post IONP exposure and for OLN-93 
cells treated for up to 3 d with IONPs though also in these two cell types transient ROS 
formation was observed (Hohnholt and Dringen, 2011; Geppert et al., 2012). However, 
in these cells iron liberated from IONPs might have been safely stored in ferritin which 
was upregulated after IONP treatment in astrocytes and OLN-93 cells (Geppert et al., 
2012; Hohnholt et al., 2011).  
Cultured neural cells appear to suffer from IONP-derived stress only when cellular IONP 
levels cross a certain threshold which differs between the cell types and might depend on 
iron content, IONP type and time of incubation (Table 3.2). This view is supported by 
literature data on cultured neurons, astrocytes, microglia and oligodendrocytes (Pickard 
and Chari, 2010; Rivet et al., 2012; Sun et al., 2013; Jenkins et al., 2013). Also presence 
of a protein corona might reduce toxicity by protecting IONPs from degradation for a 
certain time. At least for astrocytoma 1321N1 cells the corona (or a portion of it) is 
preserved during intracellular trafficking of polystyrene NPs (Wang et al., 2013). In 
general, results of toxicity in cultured brain cells are difficult to compare due to varying 
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experimental conditions and IONP types between the studies (Table 3.2; Pickard and 
Chari, 2010; Wu et al., 2013a; Sun et al., 2013). In addition, different types of viability 
assays have been used in such studies which strongly differ in their potential to 
demonstrate acute and/or delayed toxicity (Hohnholt et al., 2014). 
 
3.3. Implications of the results for the in vivo situation 
The data obtained on cultured brain cells in the present thesis and by others are likely to 
have implications for the in vivo situation. IONPs can enter the brain via different routes 
(Figure 3.3). When IONPs are applied intravenously, e.g. as contrast agent (Weinstein et 
al., 2010) or for treatment of anemia (McCormack, 2012), they are rapidly coated with a 
corona of serum proteins (Sakulkhu et al., 2014) and may enter the brain through an 
intact BBB via transcytosis (Figure 3.3a; Yan et al., 2013). However, due to low cellular 
uptake of IONPs in presence of a protein corona (chapters 2.2 and 2.4; Geppert et al., 
2013; Fleischer et al., 2013), the amount of IONPs which translocates into the brain is 
likely to be quite low and may not cause adverse effects. Indeed, in vitro models of BBB 
describe a low transfer of IONPs from endothelial to brain cells (Kenzaoui et al., 2013; 
Thomsen et al., 2013) and little transfer of IONPs into the brain was reported in mice 
and rats compared to liver and spleen (Jain et al., 2008; Wang et al., 2010). 
Astrocytes cover the blood vessels (De Bock et al., 2014) and would be the first cells 
coming in contact with the IONPs. After IONP uptake, astrocytes which are the least 
IONP-vulnerable neural cell type, will store IONP-derived iron safely as ferritin (Figure 
3.3a). However, it should be considered that astrocytes do not cover the entire BBB 
(Virgintino et al., 1997) and that the BBB at the pineal gland or hypophysis is more 
permeable than at other regions (Wislocki and Leduc, 1952; Arvidson and Tjalve, 1986; 
Stehle et al., 2011). In such areas, more IONPs may escape the astrocytes and might 
come in contact with microglia, oligodendrocytes or neurons.  
Compared to physiological situations with intact BBB, higher doses of IONPs might 
occur in brain at sites of injuries with a damaged BBB (Figure 3.3b) or when the BBB is 
made permeable on purpose by treatment with mannitol (Mejias et al., 2010; Kozler et 
al., 2013; Blanchette et al., 2014). Then, IONPs would have contact to all brain cell types 
(Figure 3.3b). In this case, microglia are likely to accumulate most of the IONPs as 
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observed also in humans and mice after intravenous administration of IONPs for 
diagnostics of pathological conditions (Neuwelt et al., 2004; Taschner et al., 2005; Tysiak 
et al., 2009;).  
 
 
Figure 3.3 Exposure of brain cells to IONPs in vivo. a) IONPs are 
transcytosed through the intact blood-brain barrier (BBB) and are likely to 
be taken up predominantly by astrocytes which have the capacity to store 
IONP-derived iron as ferritin. b) IONPs can enter the brain easily in large 
amounts if the BBB is impaired. Under such conditions IONPs will be 
taken up predominantly by microglia and to lesser extent by astrocytes, 
neurons and oligodendrocytes. c) After inhalation, IONPs invade the brain 
through sensory neurons of the olfactory bulb and may thereby directly 
harm these neurons. The enhanced levels of IONPs in the brain will be 
mostly taken up by microglia. d) For hyperthermia treatment, IONPs are 
injected into brain tumors. In close proximity to the injection, they may be 
mainly accumulated by microglia. Adapted and modified from chapter 1.4. 
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In case of direct injection of IONPs for magnetic fluid hyperthermia (Wankhede et al., 
2012) very high concentrations (around 2 M) of IONPs are applied (Jordan et al., 2006; 
van Landeghem et al., 2009). Post mortem studies have revealed that besides tumor cells 
mainly macrophage-like cells took up the administered IONPs (van Landeghem et al., 
2009). The nature of the macrophages was not described and might be microglia and/or 
peripheral macrophages entering the brain through a damaged BBB (Tysiak et al., 2009). 
 
 
Figure 3.4 Potential effects of IONP exposure of microglia in vivo. 
Exposure of microglia to IONPs may have different consequences 
depending on the amount of accumulated IONPs. Below a threshold level, 
IONPs might not damage the cells but may result in alterations in iron 
content and thereby facilitating neurodegenerative disorders. Above a 
threshold level, accumulated IONPs may cause microglial release of pro-
inflammatory cytokines which are neurotoxic and/or lead to cell death of 
microglia which compromise brain microglial functions in neuroprotection 
or phagocytosis.  
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The currently available data on IONP toxicity suggest that in brain predominant IONP 
uptake by microglia has adverse effects. An overview of possible consequences of an 
IONP exposure to microglia in brain is shown in Figure 3.4. In the best case, the amount 
of IONPs is below a threshold and no toxicity occurs (Figure 3.4). However, dependent 
on the iron content, ROS might be generated in microglia and the extent of oxidative 
stress might trigger apoptosis or necrosis (Burlacu et al., 2001). Apoptotic vesicles would 
be cleared by other microglia (Neumann et al., 2009; Napoli and Neumann, 2009) but 
necrosis would also stimulate a pro-inflammatory response in microglia (Pais et al., 2008) 
which is connected to neurodegeneration (Figure 3.3; Smith et al., 2012a). Cell death of 
microglia in general would decrease the number of microglia in the region of incident 
leading to a reduced microglial potential to defend against intruders or to help in 
neuroprotection. Moreover, microglia can become activated after IONP application as 
reported in vivo and in vitro (Wang et al., 2011a; Xue et al., 2012) and thereby might 
release neurotoxic cytokines under such conditions (Figure 3.4; Correale, 2014) though 
there are contradictory reports (chapter 2.3; Pickard and Chari, 2010). Activated 
microglia have in addition been reported to discriminate poorly between viable and 
apoptotic neurons and can promote neuronal death by so called phagoptosis which 
describes killing viable cells by phagocytosis (Brown and Neher, 2012). This process is 
even stimulated if neurons suffer from oxidative stress (Brown and Neher, 2012) which 
might be also promoted by IONP exposure (chapter 1.4; Deng et al., 2014).  
So far it is not clear how much IONPs enter the brain via the different routes under 
physiological or pathological conditions and if the local concentration might be 
sufficiently high to cause adverse effects in humans. However, alterations in iron 
concentrations in brain have been reported to be involved in neurodegenerative disorders 
such as Alzheimer’s, Parkinson’s or Huntington’s disease (Batista-Nascimento et al., 
2012; Urrutia et al., 2014; Wong and Duce, 2014). Hence, accumulation of IONPs, 
gradually release of iron ions and their distribution in brain might also under non-
cytotoxic conditions alter the neural iron metabolism (Figure 3.4) and facilitate 
progression of such disorders over time. However, the direct role of iron in these diseases 
is unclear and it remains to be elucidated whether iron is a source or a consequence of 
these diseases (Batista-Nascimento et al., 2012).  
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3.4. Future perspectives 
3.4.1. Synthesis of fluorescently labeled iron oxide nanoparticles 
The fluorescently labeled IONPs have been proven to be a useful tool for visualization of 
IONPs in cultured brain cells by fluorescence microscopy. However, further 
improvement of BP-IONPs might be beneficial to prevent non-BP-IONP-associated 
fluorescence as described above (chapter 3.1.2). For instance, more washing steps after 
coating IONPs with BP-labeled DMSA might be helpful as reported in a similar labeling 
protocol in which also DMSA was covalently modified to rhodamine and fluorescein. 
Therein, no artifacts such as staining of nuclei were seen (Bertorelle et al., 2006). 
Alternatively, fluorescent dyes could be embedded into a stable silica shell around IONPs 
(Peng et al., 2014) from which the dye cannot elute.  
 
3.4.2. Mechanism of accumulation of iron oxide nanoparticles under serum-free 
conditions 
In order to analyze the unknown uptake mechanism of IONPs in absence of serum, cells 
may be depleted in specific proteins of a given endocytotic process such as clathrin, 
caveolin or ADP-ribosylation factor 6 by small interfering RNA (Canton and Battaglia, 
2012; Sahay et al., 2010). This approach would be more specific than usage of 
endocytosis inhibitors (Ivanov, 2008). Moreover, immunocytochemical techniques, either 
by the use of fluorescence microscopy or TEM, should be exploited for visualization of 
certain pathways. For example, co-localization studies with known cargos of the single 
endocytotic pathways or transfection of a certain protein fused with green fluorescent 
protein are established methods to investigate the uptake mechanism of NPs (Sahay et al., 
2010). In the former case, transferrin (Qaddoumi et al., 2003; Barua and Rege, 2009) and 
cholera toxin B or Simian virus 40 (Qaddoumi et al., 2003; Wang et al., 2011b) are used 
for studying clathrin- and caveolin-mediated endocytosis, respectively. Similar studies 
could be performed for macropinocytosis, for example by co-localizing fluorescently 
labeled IONPs with ricinB-quantum dots which are internalized via macropinocytosis 
(Iversen et al., 2012).  
In addition, uptake of IONPs by endocytotic-independent invagination of the plasma 
membrane would be very interesting to study. A straightforward approach would be to 
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knock-down or inhibit all possible endocytotic pathways. However, this is difficult to 
achieve since the available inhibitors are not sufficiently specific, the total incapability of 
endocytosis might be harmful to cells and/or there might be unknown pathways which are 
involved in IONP uptake. As alternative, to at least prevent energy-dependent endocytosis 
cells could be depleted of energy by glucose deprivation (Mattson et al., 1993; Almeida et 
al., 2001) and/or application of the respiratory chain inhibitor sodium azide or the 
mitochondrial ATP-synthase inhibitor oligomycin A as described in astrocytes and 
neurons (Swanson et al., 1997; Pamenter et al., 2012).  
 
3.4.3. Binding, uptake and fate of iron oxide nanoparticles in cultured brain cells 
The reason for differences or similarities of different types of neural cells regarding IONP 
accumulation and cellular localization of IONPs should be further investigated. The first 
event in uptake is the attachment of IONPs to the plasma membrane which should be 
investigated in more detail and quantified. Atomic force microscopy is able to reveal the 
force of interaction between IONPs and the cell surface and could be used to test for 
differences in IONP adsorption between astrocytes, microglia, oligodendrocytes and 
neurons as well as between incubation conditions as reported recently for IONPs and 
lung epithelial cells in absence and presence of serum (Pyrgiotakis et al., 2014). 
Moreover, a quantification of IONPs attached to the cell membrane can be achieved by 
biotinylation of the plasma membrane, separation of the biotinylated membrane by 
neutravidin beads after cell homogenization and subsequent determination of the iron 
content for the obtained fractions (deBlaquiere and Burgess, 1999). Attachment of 
IONPs to the cell surface could also be visualized with scanning electron microscopy 
which would also reveal morphological responses of the cells to IONPs on the 
ultrastructural level as seen for primary cortical neurons (Rivet et al., 2012).  
Using TEM and immunocytochemical approaches, IONPs should be localizes within 
astrocytes, oligodendroglial cells and neurons as in these cells IONPs were not 
translocated rapidly to lysosomes, in contrast to microglia. Incubation times with IONPs 
should be elongated to examine the fate of IONPs by immunocytochemical staining for 
stages of endosome differentiation such as early/late endosomes, lysosomes or 
caveosomes which would help to identify the IONP-containing vesicles. Alternatively, 
IONPs could be functionalized with a pH-responsive fluorescent dye such as 8-
hydroxypyrene-1,3,6-trisulfonic acid, Oregon Green, fluorescein and/or rhodamine B 
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(Overly et al., 1995; Benjaminsen et al., 2011) but also with the pH-dependent Ageladine 
A (Bickmeyer et al., 2008; Bickmeyer et al., 2010) revealing at least information on the 
pH of IONP-containing vesicles. When IONPs enter lysosomes, iron is released 
progressively from IONPs (Levy et al., 2010; Malvindi et al., 2014; Shukla et al., 2014). 
To reveal the time frame and the amount of iron liberated from internalized IONPs, iron 
ions could be visualized by using iron selective fluorescent probes such as an alanine 
substituted rhodamine derivative or a BODIPY-cyanine-pyridine derivative (Li et al., 
2011a; Saleem et al., 2014).  
Moreover, it would be interesting to study the size dependency of IONP uptake and 
toxicity in neural cells. The IONPs used in the present thesis as well as in former studies 
of our group were not monodisperse i.e. the dispersion were composed of IONPs with 
varying sizes of single NPs as well as of IONP aggregates in dispersion. As endocytotic 
pathways are size-dependent, IONPs with a single size might be taken up by a selected 
pathway (Canton and Battaglia, 2012) which would enlighten the role of certain pathways 
in accumulation of IONPs.  
 
3.4.4. Effects of an iron oxide nanoparticle exposure to cultured brain cells 
So far, the vast majority of studies on consequences of IONPs on cultured brain cells 
tested only for cell viability. However, sub-toxic doses of IONPs still might influence cell 
type-specific functionality. Electrophysiology techniques could be used to study neuronal 
function as it was recently reported that the burst rate of cultured neurons was decreased 
by IONPs in primary cortical neurons (Gramowski et al., 2010). Astrocytes should be 
studied for potential effects of IONPs on astrocytic functions including calcium waves, 
release of gliotransmitters and supporting other neural cells (Verkhratsky and Parpura, 
2010; Peters and Connor, 2014). In addition, it would be interesting to test for ability of 
astrocytes to protect IONP-harmed neural cells. Preliminary experiments suggested less 
vulnerability of microglia in astroglia-rich primary cultures as compared to primary 
microglia cultures (data not shown). The effect of IONPs on mobility of microglia by 
migration assays (Yu et al., 2014) and release of cytokines (Stenken and Poschenrieder, 
2015) should be tested. Migration assays are usually performed by scratching the cell layer 
and monitoring the relocation of cells (Yu et al., 2014). Such experiments revealed at least 
for carbon nanotubes no change in microglial mobility (Cyrill Bussy, personal 
communication). Also the reported phagoptosis of viable but stressed neurons by 
102  Summarizing discussion 
microglia (Brown and Neher, 2012) could be investigated by using co-cultures of 
microglia and IONP-treated neurons. To study effects of IONPs on oligodendroglial 
functionality, the formation and maintenance of myelin sheaths could be tested in co-
cultures with neurons (Barateiro and Fernandes, 2014).  
Toxic events might be reduced or even prevented by functionalization of IONPs. Herein, 
it is possible to target IONPs towards certain cell types by introducing a ligand or antibody 
to a cell type specific receptor or membrane protein into the coat in order to overcome 
the predominant microglial IONP uptake. For this, IONPs could be functionalized e.g. 
with antibodies or ligands against the astrocytic excitatory amino acid transporter 2 
(Roberts et al., 2014) or CD44 (Grabrucker et al., 2011), oligodendroglial myelin-specific 
proteins such as myelin-basic protein and myelin-associated glycoprotein (Peters and 
Connor, 2014) or neuronal proteins such as neural cell adhesion molecule 1 (Grabrucker 
et al., 2011). To support cells against oxidative stress, the coat could be modified with 
antioxidants as it was previously reported for gold and selenium NPs which were 
functionalized with Trolox (an analogue of vitamin E), salvianic acid and 11-mercapto-1-
undecanol, respectively and which could scavenge ROS in cell-free attempts as well as in 
vitro and in vivo (Du et al., 2013; Li et al., 2011b; Nie et al., 2007).  
 
3.4.5. Investigations on uptake and effects of iron oxide nanoparticles in vivo 
The most important aspect for risk assessment and investigations on therapeutic potential 
of IONPs in biomedical application are in vivo studies. Though some publications 
suggest entry of IONPs into brain through the intact BBB (Jain et al., 2008; Wang et al., 
2010; Yan et al., 2013), the data are not so clear due to limited resolution of the 
published microscopic images. Hence, different application modes should be used to 
investigate possible routes of entry, the amount of iron reaching the brain, and a time 
dependent distribution of IONPs within the brain. For such studies, fluorescent IONPs 
should be applied intravenously, intracerebrally or intranasally in rodents and the IONPs 
in brain and other tissues could be visualized in slices by fluorescence microscopy 
coupled with immunocytochemical staining, by Perls’ iron staining and/or by TEM after 
certain incubation periods.  
For the brain, parameters of toxicity such as ROS generation or apoptosis as well as 
changes in morphology of the neural cell types should be analyzed after an IONP 
exposure, e.g. if microglia turned into the activated state as reported in mice after 
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intranasal application (Wang et al., 2011a). Moreover, behavioral studies on rats or mice 
are highly warranted to investigate whether IONP exposure may have a long-term effect 
on cognition since data on that issue are scarce (chapter 1.4). In order to study whether an 
altered neural iron content in IONP-treated brains promote neurodegenerative disorders, 
application of IONPs to animal models for Alzheimer’s and Parkinson’s disease (Bove 
and Perier, 2012; Dujardin et al., 2014) would be an option. In this context, analysis of 
the brain from IONP-treated animals for pathological alterations and characteristics of the 
neurodegenerative disorders should be performed. 
In addition to potential adverse effects, IONPs might also be beneficial when applied as 
drug delivery system. As vehicle for therapeutics, IONPs may be used to treat disorders 
such as Alzheimer’s or Parkinson’s disease as reported recently for functionalized carbon 
nanotubes (Professor Dr. Kostas Kostarelos, personal communication). Iron deficiency in 
brain which causes disorders like restless legs syndrome is not easy to treat by peripheral 
application of low molecular weight iron due to poor permeability of the brain for iron 
(Hare et al., 2013). Due to the possibility to functionalize IONPs for good permeation of 
the BBB into the brain, IONPs might also be a valuable tool to treat iron deficiency.  
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